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Salmonella Typhimurium is a Gram-negative bacterial pathogen and a common cause of
gastroenteritis in humans. The organism utilizes a multitude of well-studied virulence
factors to invade and replicate in host intestinal epithelial cells and macrophages.
Interestingly, Salmonella is also capable of localizing to tumors in in vivo model systems,
and while the typical route of Salmonella infection and pathogenesis has been thoroughly
investigated, the behavior of Salmonella in the tumor microenvironment has not.
Therefore, to investigate Salmonella and host behavior during bacterial-neoplastic cell
interactions, I utilized two high-throughput screens. In the first, I designed a
bioluminescent transposon-reporter trap to identify specific Salmonella genes activated in
the context of cancer cell co-culture conditions. Through this work, I identified five
Salmonella genes reproducibly activated by co-culture with cancer cells, and further
isolated the activating stimulus to low pH. Because low pH is a common characteristic of
the tumor microenvironment, I also demonstrated the pH inducibility and reversibility of
Salmonella gene activation in tumors ex vivo and in vivo. In a separate study, to better
ii

understand how host neoplastic cells respond to Salmonella, I investigated the ability of
Salmonella to induce pro-inflammatory responses in HCT116 colon carcinoma cells,
specifically, NF-κB activation. Then, I performed a high-throughput siRNA screen to
identify novel host kinases and phosphatases involved in detection of Salmonella and
activation of NF-κB signaling. For this work, I used a reporter construct consisting of an
IκBα-firefly luciferase fusion protein transcriptionally activated by NF-κB. The reporter
permitted imaging of both degradation of the NF-κB negative inhibitor IκBα and its
resynthesis, which is dependent on NF-κB activation, following stimulus with
Salmonella. The host kinase, NME3, was identified in the screen as a specific modulator
of NF-κB. Knockdown of NME3 prevents proper activation of NF-κB signaling
pathways in HCT116 cells exposed to Salmonella, demonstrating the role of this kinase
as a positive regulator of NF-κB pro-inflammatory signaling in colon carcinoma cells.
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CHAPTER 1

Introduction
1.1 Introduction to Salmonella
The genus Salmonella represents a large and diverse collection of Gram-negative bacteria
belonging to the family Enterobacteriaceae [1]. It consists of two species of facultatively
anaerobic bacilli, S enterica and S bongori [1]. Six subspecies exist within the species
Salmonella enterica of which one, Salmonella enterica enterica, accounts for 59% of all
Salmonella isolates, are the only strains regularly found in warm-blooded animals, and
include 99% of disease-associated isolates [1]. This subspecies is further divided into
multiple serovars based on antigenic determinants of the bacterium, such as its flagellin
protein and outer polysaccharide structure [1]. Salmonella enterica enterica includes the
pathogenic serovars Salmonella Typhimurium, Salmonella Enteritidis and Salmonella
Typhi [1].
In the environment, Salmonella are maintained as normal flora in multiple diverse
vertebrate animals including chickens, cattle and reptiles [2]. Perhaps due to its ubiquity
in the environment, Salmonella is one of the leading causes of food poisoning in the
United States each year [3]. The organism typically causes 30,000-40,000 confirmed
infections in the United States annually, approximately 400 of which are fatal, although
the true number of Salmonella infections is likely much higher [3]. When transmitted to
humans, typically by contaminated food and water, Salmonella cause an infection termed
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Salmonellosis, which most commonly results in a self-limiting gastroenteritis [4]. S.
Typhimurium is also capable of more severe sequelae and can cause endocardidits and
vascular infections by adhering to endothelial cells. In the most severe cases, Salmonella
can progress to a systemic bacteremia in infected hosts by replicating and surviving
within macrophages.

1.2 The Pathogenesis of Salmonella Typhimurium
Invasion
The pathogenesis of Salmonella Typhimurium has been studied in detail and much is
known about its virulence factors and the molecular mechanisms used during infection of
its host (Figure 1-1). During the typical route of infection, Salmonella bacteria travel
through the stomach to the intestine following ingestion [4]. Once in the intestinal
lumen, the bacteria utilize type 1 fimbrae to attach to enterocytes [5]. Local
environmental conditions in the distal small intestine, the preferred site of Salmonella
invasion, induce bacteria to activate the Salmonella pathogenicity island 1 (SPI-1) genes
[6, 7]. SPI-1 refers to one of multiple clusters of virulence genes in the Salmonella
genome and encodes multiple important virulence genes, including those encoding a type
three secretion system (TTSS) and effector proteins that target the host cell [8-14]. The
SPI-1 TTSS is a needle-like apparatus with structural similarity to bacterial flagellin [15,
16]. It consists of a basal body, anchoring the structure to the bacterial cell membrane, an
ATPase motor and a translocon made of repeating filament protein, capable of delivering
effector proteins directly from the bacterial cytosol into the eukaryotic cell [15, 16]. The
SPI-1 TTSS has been shown to translocate at least 13 proteins [14]. Many of the secreted
2

effectors are involved in modulating host actin to induce Salmonella uptake into the host
cell, indicating an essential role for the SPI1 in bacterial invasion [14]. One of these
effectors, SipC, has two important functions. SipC acts both as an outer structural
component of the TTSS translocon by forming a pore in the target cell membrane, as well
as a nucleator of host actin filaments [17, 18]. As the first secreted effector, SipC
therefore begins the host cytoskeletal filamentation process. The second secreted effector
protein, SipA, promotes and enhances the actin filamentation process set into motion by
SipC [19]. In addition to the initial actin filamentation steps induced by SipC and SipA,
Salmonella utilizes additional effectors to further induce branching of actin filaments,
which fuels the host cell membrane ruffling that promotes bacterial uptake. Two of these
effectors, SopE and SopE2, act as guanine exchange factors (GEFs) for host Rac and
Cdc42 GTPase proteins [20-22]. The GEF activity of SopE and SopE2 enhances the
activity of these host cell molecular switch GTPases, which induce actin branching and
cytoskeleton assembly [20-22]. The cooperative actions of SipC and SipA with SopE
and SopE2 cause drastic host actin filamentation that results in full uptake of the bacteria
into a Salmonella Containing Vacuole (SCV) within the host intracellular space.
Following bacterial entry, Salmonella effector proteins are also responsible for restoring
the host cell actin cytoskeleton to its normal architecture. SptP acts as a GTPaseactivating protein (GAP), and reverses the action of SopE by inactivating the host
GTPases Rho and Cdc42 [23]. By taking advantage of the different stabilities of the
SopE and SptP proteins, Salmonella can cover their tracks and reduce the possibility of
alerting the immune system of their presence in the newly infected host cell[24]. SopE,
as mentioned previously, is a GEF, promoting actin filamentation in target cells. While
3

SopE and SptP are injected by the SPI-1 TTSS in similar amounts, SopE is quickly
targeted and degraded by the host proteasome [24]. Meanwhile, SptP persists to return
the host cell membranes to their normal architecture [24].

Intracellular Survival
When Salmonella reach the intracellular compartment during infection, they utilize an
additional set of effectors to modulate host cell trafficking and preserve the SCV.
Within the host cell cytosol, Salmonella employ diverse mechanisms to control the
composition, environment and intracellular location of the SCV. In general, Salmonella
within intestinal epithelial cells and those engulfed by infiltrating macrophages during an
intestinal infection respond similarly, by modulating intracellular trafficking and
replicating within their host cell [25].

Immediately after bacterial entry, the SCV is

enriched in early endosome membrane markers [26]. Later, the SCV gains late
endosomal and lysosomal markers, localizes to a juxtanuclear position, and acidifies [27,
28]. Acidification of the SCV promotes activation of virulence genes and a second TTSS
encoded by the SPI-2 pathogenicity island, while simultaneously repressing the
previously used invasion genes of SPI-1 [29, 30]. SPI-2 virulence factors have been
implicated in Salmonella modulation of host intracellular trafficking and signaling
pathways as well as bacterial replication. SPI-2 knockouts are capable of invading host
cells, but cause a much less severe disease in vivo, showing that these activities are
required for a productive systemic infection [31]. It is unclear exactly how Salmonella
modulate host cell trafficking while in the SCV, but, like the invasion process, the host
cytoskeletal membrane dynamics are largely involved. Sixteen effectors have been
identified as secreted products of the SPI-2 TTSS and at least half of these have been
4

known to associate with the endosomal membrane system [32]. Within four to six hours
of bacterial invasion of host cells, Sif (Salmonella induced filament) formation is
observed [33, 34]. These membrane extensions of the SCV are enriched in lysosomal
proteins and may form along microtubules [33, 34]. While Sif formation and function are
not fully understood, Salmonella dedicates multiple effector proteins (SseF, SseG, SseJ
and SifA) to their maintenance and robustly induces their formation in vitro, indicating
their relevance to bacterial virulence and intracellular replication.

1.3 Host Immunity to Salmonella
The Innate Immune Response to Salmonella
To detect and control Salmonella infection, hosts rely on the rapid response of innate
immunity mechanisms. Innate immunity is considered the first line of defense against a
pathogenic organism such as Salmonella and consists of extracellular secreted defense
molecules, host cell receptors and intracellular signaling pathways. Human cells display
multiple receptors designed to recognize pathogen associated molecular patterns
(PAMPs) and alert the host as to the presence of a foreign organism. PAMPs include
bacterial lipospolyssacharide (LPS), peptidoglycan and flagellin. PAMP receptors are
referred to as pattern recognition receptors (PRRs) and those expressed in humans
include Toll-like receptors (TLRs) and nucleotide oligomerization domain receptors
(NODs). Binding of a PAMP to one of these receptors causes activation of multiple host
cell signaling pathways responsible for inducing inflammation, recruiting immune cells
and releasing cytokines.

5

Toll-Like Receptors
One of the major PRRs in the innate immunity system is the Toll-like receptor. The first
Toll receptor was discovered in Drosophila as a necessary player in proper development,
but was later linked to immunity when Toll mutant flies were shown to be more
susceptible to fungal infection. To date, 10 different TLRs have been identified in
mammalian cells (1-9 pictured in Figure 1-2) [35]. TLRs are type 1 transmembrane
proteins consisting of an N-terminal extracellular (or intra-endosomal) region of leucinerich repeats involved in recognizing PAMPs and a cytoplasmic domain necessary for
downstream signal transduction [35]. The cytoplasmic domain of TLRs closely
resembles the IL-1 receptor cytoplasmic domain, and therefore both of these are called
TIR or Toll/interleukin receptor domains [36]. All TLRs are similar in their structures
and respond to foreign antigens. However, TLRs are diverse in ligand specificity,
subcellular location, required adapter proteins and induction of downstream signaling
pathways. TLR3, TLR7, TLR8, and TLR9 respond to intracellular stimuli and are
located on endosomal membranes [35]. TLR3 is activated by double-stranded RNA
while TLR7 and TLR8 have been shown to respond to single-stranded RNA, both of
which are formed during a viral infection. TLR7 and TLR8 have also been demonstrated
to respond to synthetic imidazoquinolines, which are small antiviral compounds [37].
TLR9 reacts to viral and bacterial CpG DNA. The remaining TLRs: TLR2, TLR1,
TLR6, TLR4 and TLR5 are typically found on the cell membrane and bind extracellular
stimuli [35]. TLR2 alone recognizes peptidoglycan, but it also may heterodimerize with
TLR1 or TLR6 to respond to bacterial lipopeptides. TLR4 and TLR5 are activated by
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bacterial lipopolysaccharide(LPS) and flagellin, respectively. TLR10 has been
discovered recently, and its specific ligand is not yet known [38].
Once a TLR is activated, the timing of signal transmission and downstream effects are
dependent on adapter proteins recruited to the cytoplasmic TIR domain of the TLR. In
general, TLRs can be described as either MyD88-dependent or MyD88–independent
based on the TIR-domain adapters utilized. All TLRs except TLR3 and TLR4 require
MyD88, though TLR4 can signal through a MyD88-dependent or MyD88-independent
pathway [39, 40]. Some TLRs signal directly to MyD88, but TLR1, TLR2, TLR4 and
TLR6 use a bridge adapter protein called TIRAP [40]. Once activated, MyD88 first
recruits IRAK4 (IL-1R associated kinase), which in turn recruits IRAK1 and TRAF6 [41,
42]. This leads to recruitment and activation of the TAK1/TAB kinase complex [43, 44].
The TAK1/TAB kinase complex activates downstream targets including both MAPK
(mitogen-activated protein kinase) pathways and the NF-κB (nuclear factor kappa-lightchain-enhancer of activated B cells) pathway through IKK (inhibitor of κB kinase) [44].
In the case of TLR3 and TLR4, which can signal independently of the MyD88 adapter,
TRIF binds directly to the TIR domain of TLR3 to transduce the signal, or TRAM serves
as an adapter to TRIF in the case of TLR4 [40, 45]. TRIF activates TRAF6 and RIP1,
leading to IKK activation, and downstream NF-κB signaling as in MyD88-dependent
TLR activation, but on a much different timescale than MyD88 dependent TLR signaling
[42, 46]. In addition to NF-κB, IRF3 (interferon regulator factor 3) is a key transcription
factor activated in the MyD88-independent pathway [47]. In this signaling node, TLR3
and TLR4 are both capable of activating non-canonical IKKs through TRAF3 [48]. The
non-canonical IKKs (TBK1 and Ikke/IKKi) activate IRF3, which can then dimerize and
7

translocate to the nucleus, where it activates transcription at IFN-stimulated response
elements (ISRE) [48]. IRF3 has also been shown to form a complex with NF-κB and
ATF2/C-Jun called the enhanceasome, which activates interferon beta transcription [48].
Although different TLRs have similar structures, diversity in response is achieved by the
intracellular adapters and signaling proteins targeted by each TLR.

Toll-Like Receptor 5
Toll-like receptor 5 was discovered in 1998 and in 2001 was shown to recognize both
Gram-positive and Gram-negative bacterial flagellin, and to robustly induce IL-6
production in vivo in a MyD88-dependent manner [49]. TLR5 engagement leads to
MAPK and NF-κB activation and the eventual downstream activation of 500 genes
including chemokines, stress response genes and anti-apoptotic genes [50]. The receptor
is expressed on dendritic cells, monocytes and epithelial cells, and is likely involved not
only in classic response to pathogens, but also in keeping proper gut homeostasis [51,
52].
TLR5 binds most bacterial flagellin. In the Salmonella FliC protein, the specific
recognition site has been isolated to a 13 amino acid sequence [53]. This sequence is
required for flagellin filament polymerization and therefore bacterial motility,
demonstrating the precision of the host innate immunity response [53]. Further, previous
studies have demonstrated that flagellin is the major proinflammatory determinant of
Salmonella in some cases and that flagellin exposure elicits a strong activation of
cytokine release by host cells [50].
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TLR5 activity is robustly pro-inflammatory, and therefore multiple mechanisms exist to
keep activity in check. The cell is capable of down-regulating TLR5 signaling thru PI3K
(phosphoinositide 3-kinase), which prevents over-expression of proinflammatory genes
by regulating MAPK signaling [54]. There is also evidence that the host protein Muc1
can interact with flagellin and dampen downstream TLR5 signaling [55]. The location of
TLR5 also contributes to its control. In vivo, TLR5 expression is limited to the basolateral
membrane of the colon, thereby preventing overactive signaling due to flagellated
commensal microbes in the intestinal lumen [56]. Flagellin must therefore breach the
gastrointestinal barrier to induce signaling in normal cells. Still, TLR5 is readily able to
be activated by flagellin of commensals as well as pathogens, indicating that the
accessibility of flagellin, and not the pathogenicity of the species, is the main factor in
TLR5 activation [57].
As an integral activator of inflammatory signaling, TLR5 loss or dysfunction has very
serious consequences in the host. A TLR5-deficient mouse model has been developed
that fails to activate any proinflammatory pathways in response to flagellin, providing a
valuable and informative system to study the importance of TLR5 in vivo. The mice
develop a severe metabolic syndrome marked by obesity and insulin resistance in
addition to a tendency to develop spontaneous colitis [58, 59]. These phenotypes may be
a result of changes in the composition of the microbiota, identifying a role for TLR5 in
maintenance of proper gut homeostasis [58, 59].
TLR5 loss has differing effects on Salmonella pathogenesis, depending on the route of
infection. TLR5 knockout mice develop more severe gastroenteritis in an antibiotic
pretreatment mouse model of Salmonella intestinal infection [60]. However, the mice are
9

resistant to Salmonella infection in a typhoid-mouse model, and this resistance is not
specific to flagellated Salmonella [60]. Finally, TLR5 knockout mice demonstrate higher
levels of basal expression of certain innate immunity genes and of IgG and IgA,
indicating constitutively active immune responses may protect mice in the typhoid model
[60]. The complicated role of TLR5 uncovered by the TLR5-deficient mouse
demonstrates the need to further characterize the exact downstream signaling pathways to
understand how Salmonella interacts with its host.
TLR signaling may also promote Salmonella infection. In one study utilizing a mouse
model of gastroenteritis, Salmonella relied on induction of host pro-inflammatory
responses to target host normal microbial flora to optimally colonize the host [61]. This
may reduce competition for Salmonella, allowing the bacteria to gain better access to host
cells and promote invasion. In another study, while the researchers did not look
individually at TLR5, they showed signaling by other TLRs induced vacuolar
acidification and consequently, provided a cue to induce bacterial virulence factor
expression and secretion by intracellular Salmonella [62]. Clearly, TLR5 signaling may
lead to varied host responses to Salmonella infection, depending on the route and site of
inoculation, highlighting the need for a more thorough understanding of Salmonellainduced signaling pathways.

NF-κB Signaling
One of the major transcriptional nodes activated downstream of all TLR signaling is NFκB. NF-κB was originally discovered as a transcription factor utilized during B
10

lymphocyte development, but was later recognized as a broad transcriptional activator
used in numerous situations. NF-κB now refers to a family of multiple transcription
factors that act as master regulators and integrators of host innate immunity and as
promoters of inflammation as well as general cellular responses to stress and cellular
differentiation and development. Specific receptors including TLRs, Tumor Necrosis
Factor Receptor (TNFR), and Interleukin-1Receptor (IL-1R) signal through NF-κB to
activate target genes involved in cytokine production, cell adhesion, immunoreceptors,
and additional transcription factors [63]. NF-κB signaling pathways can generally be
divided into two types: canonical and non-canonical signaling [64]. Canonical NF-κB
signaling includes the typical inflammatory-associated NF-κB signaling and occurs on a
much shorter timescale than non-canonical signaling [64].
The NF-κB family consists of 5 proteins with a Rel homology domain (RHD): RelA,
RelB, cRel, p50 and p52 [63]. These monomers are capable of associating via their
RHDs into 15 potential homodimers and heterodimers [63]. The primarily used NF-κB
dimer in the canonical pathway is the RelA-p50 heterodimer, where RelA contains the
transactivating domain [63]. In a resting state, the NF-κB heterodimer is held in the cell
cytoplasm by one of three classical IκB proteins, IκBα, IκBβ, or IκBε, which bind NF-κB
through their ankyrin repeats domain (ARD) [63]. When an upstream receptor, such as a
TLR, is activated, signal transduction pathways lead to activation of IKK kinase
complexes containing IKKγ , IKKα and IKKβ [63]. Activated IKK phosphorylates IκBα,
which induces recruitment of an E3 ubiquitin ligase [63]. IκBα is ubiquitinated and
subsequently degraded by the proteasome, leaving the nuclear localization signal (NLS)
of the NF-κB dimer unmasked [63]. NF-κB translocates to the host nucleus, where it
11

activates host genes involved in management of stress response and inflammation as well
as its own negative regulator IκBα, making this a classic negative feedback loop [63].
Because NF-κB is such a crucial regulator in host innate immunity, Salmonella has
evolved multiple mechanisms to evade host detection and activation of NF-κB. First, the
organization of flagellin itself is such that the immunogenic portion is predominantly
hidden in the polymerized protein [53]. It seems Salmonella has evolved a way to mask
the majority of flagellin’s immunostimulatory activity as it is polymerized on the
bacterial surface. Salmonella also secretes multiple effectors capable of down-regulating
NF-κB signaling. One of these, SspH1, translocates to the host nucleus, where it inhibits
NF-κB transcriptional activation [65]. Another Salmonella effector protein, AvrA, is also
injected into the host cell cytoplasm by the SPI-1 TTSS and seems to play an important
role in reducing host proinflammatory signaling [66, 67]. Although its exact mechanisms
are not fully understood, it blocks NF-κB activity, perhaps by acetyltransferase activity
on downstream players in the NF-κB pathway [66, 67]. NF-κB represents a potential
block to a productive Salmonella infection, and to compensate, the pathogen positions
considerable resources into the development of an anti-NF-κB response.

1.4 Salmonella Interactions with Neoplastic Host Cells
The Inflammation-Cancer Axis
Overactive NF-κB signaling can have dire consequences for the host, indicated by the
multiple mechanisms in place that keep its activity in check. Perhaps the most important
tactic used by the host to control NF-κB signaling is NF-κB’s direct transcriptional
activation of its own negative regulator. Activated NF-κB induces transcription of IκBα,
which, after translation in the cytoplasm, is thought to translocate to the nucleus, bind
12

NF-κB, and export the transcription factor [68]. The RelA subunit of NF-κB has also
been demonstrated to interact with histone deacetylasese (HDACs), which are known to
negatively regulate transcription [69]. Further, once activated, the NF-κB signaling
pathway resists further stimulation [70]. In one study, NF-κB activation was measured
after a TNFα preconditioning step [70]. Following a 30-second exposure to TNFα, IKKmediated NF-κB activation was severely compromised for up to 120 minutes, indicating
that cells can be desensitized to NF-κB stimulatory activity, thus preventing overresponse [70].
However, even with mechanisms in place to prevent over-stimulation of NF-κB, cells
exposed to excessive amounts of proinflammatory stimuli may experience deleterious
effects. Chronic and overactive inflammation has long been suspected as a contributing
factor to cancer development, and recently, more information on how infection and
inflammation may lead to carcinogenesis has emerged. Collectively, infections and
inflammation may be at least part of the underlying cause of up to 20% of all cancer
deaths [71]. There are several known clinical associations between infection or
inflammation and cancers including Hepatitis viruses HBV and HCV in liver cancers,
Helicobacter pylori in gastric cancers and the link between inflammatory bowel diseases
(IBDs) and colorectal cancers, as well as leukemia and other cancers caused by human Tlymphotropic virus (HTLV) [72-74]. Additionally, there is evidence of genetic
polymorphisms within the TLR and IL-1β promoters that positively associate with
prostate and gastric cancers, respectively [75].
Because carcinogenesis is a lengthy and undefined process, it is difficult to effectively
study the cancer-inflammation linkage in the laboratory. However, several studies have
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produced convincing examples of how misregulated NF-κB signaling can directly
contribute to tumor formation. In a colitis-associated cancer (CAC) model in mice, the
chemical dextran-sulfate sodium salt (DSS) contributes to tumor formation by damaging
the mucosal barrier and exposing underlying cells to resident normal flora bacteria.
Inactivation of IKK-β in enterocytes of this model reduced tumor number by 80%, clearly
indicating a role for the NF-κB pathway in tumor induction in this system [76]. In another
model system, the mdr2 knockout mouse, the lack of an mdr2 transporter causes
accumulation of lipids and bile acids within hepatic cells, which results in spontaneous
tumor formation within 8-10 months [77, 78]. However, when the IκB super repressor
blocks signaling, tumor formation was blocked as well, indicating cellular stress mediates
tumor development through NF-κB signaling [77]. In another study, Oguma et al link the
TNF secreted by macrophages, presumably a result of macrophage NF-κB signaling
activation when recruited to the site of a gastric infection, with increased Wnt/β catenin
signaling and gastric tumor formation [79]. Finally, the protein HIF-1α links bacteria,
NF-κB and cancer as well. HIF-1α is a transcription factor that is stabilized and activated
in conditions of low oxygen [80]. Researchers have recently shown that following
detection of bacteria and subsequent host activation of innate immunity pathways, NF-κB
activates HIF-1α transcription, likely in response to the hypoxic conditions replicating
bacteria induce in their host [80]. Coincidentally, tumors produce low oxygen
environments as well, indicating that activation of this transcription factor in response to
bacteria also better equips the host for fitness in a pro-tumor environment. Between
epidemiological associations and the new data being uncovered in the laboratory, the link
between inflammation, infection and cancer is growing.
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Bacteria as a Cancer Therapeutic: A Historical Perspective
Interestingly, in addition to being a hypothesized contributor to cancer formation,
Salmonella has recently received consideration as a potential theraputic for cancer.
Although the typical route of Salmonella infection is gastrointestinal, which may lead to
chronic carriage or a systemic infection, Salmonella infections of the host are also
capable of another unique consequence [4]. Salmonella are capable of colonizing a host
animal at the site of a tumor in vivo [81]. Notably, a correlation between cancer remission
and coincident bacterial infection was observed as early as the 14th century [81]. In the
1800’s, the first intentional use of bacteria to treat cancer has been attributed to Dr. W.
Busch, who exposed a tumor patient to the bed linens previously used by a patient with a
Streptococcus infection [82]. Despite rapid tumor shrinkage, the woman contracted a
severe bacterial infection and died soon thereafter [82]. In later work, Dr. William Coley
pioneered the use of “Coley’s toxin”, a treatment composed of inactivated bacteria
including Streptococci and Serratia marcesens [82]. Dr. Coley reported tumor
regression, perhaps via host systemic responses involving induction of tumor necrosis
factor [81, 82]. Still, intentional infection with bacteria, especially before the advent of
antibiotic use, was generally unpredictable and difficult to control [81, 82]. The toxic
side effects and lack of reproducibility of such treatments eventually led to
discontinuation of their use [82].

Salmonella: Localization to Tumors
Recently, anaerobic and facultatively anaerobic bacteria, among other organisms, have
been shown to selectively localize to and replicate within malignant tumors. Clostridium,
Bifidobacteria, Escherichia coli, Listeria, Streptococcus pyogenes and Salmonella have
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each been used in contemporary studies exploring bacterial-based tumor treatment [82].
Salmonella appears to affect a diverse set of neoplastic cells or tumors, including:
melanomas, gliomas and neuroblastomas, renal carcinomas, and cancers of the prostate,
breast, bladder and colon [82-88]. Using noninvasive bioluminescent imaging to track
Salmonella expressing plasmid encoded luxCDABE, Yu et al showed that Salmonella
could report malignant tumor locations in living mice. Salmonella are impressively tumor
adaptable. They have been shown to localize in tumors with tumor:tissue ratios up to
9,000 times that of normal tissue, to localize to tumors in both immunocompetent and
immunocompromised mice, and to detect and replicate within metastases as well [88,
89]. In independent work, electron micrographs of excised melanoma tumors detect
Salmonella within the cytosol of melanoma tumor cells, suggesting bacteria not only
localize to, but may actually invade, malignant tumor cells [82]. However, it remains to
be definitively shown how Salmonella behave in the tumor environment. For instance, it
is not fully understood whether Salmonella are capable of invading cancer cells or what
types of cancer cells Salmonella will enter. Also, it is unclear to what extent the
molecular mechanisms of Salmonella virulence and the specific gene regulation events
during interactions with cancer cells recapitulate those utilized during a classical
Salmonella infection.

Salmonella as a Potential Cancer Therapeutic
Cancer is predicted to kill more than 500,000 people in the United States in 2011 [90]. In
this same year, more than 1.5 million Americans will be newly diagnosed with cancer
[90]. Unfortunately, despite some notable advances, many patients with cancer still must
contend with remarkably poor diagnosis and treatment options [91-93]. Diagnosis often
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occurs far too late in disease progression, after metastases decrease the odds of survival.
In general, chemotherapy and radiation therapy regimens have significant associated
systemic side effects. One way to improve the therapeutic index (overall efficacy vs.
toxicity) of cancer treatments may be to more specifically localize treatment effects to
malignant tissues.
Given its localization to malignant tumors, appropriately engineered Salmonella might
serve well as an anti-tumor agent. To date, some such efforts have exploited
Salmonella’s ability to carry tumor antigens. Others have aimed to activate the immune
response to attack tumor cells, independent of the bacteria localization to the tumor site.
Immunotherapy-based strategies are often restricted by limited knowledge of tumor
markers and their immunogenicity. Salmonella flagellin has been directly injected into
tumors in an attempt to slow their growth, a strategy that exploits flagellin as a more
general immune stimulus [87]. However, this treatment failed to effect growth of a
weakly immunogenic tumor. Attenuated Salmonella expressing human IL-2 can also
retard tumor growth in mice [94]. Yet, while Salmonella-based immunotherapy has
enjoyed moderate success, utilizing it to treat neoplastic tumors seems contradictory,
given that such tumors are a noted site of immunosuppression. It is likely that further
progress in understanding – and perhaps exploiting – the interactions between bacteria
and tumors can be made by investigating the mechanisms behind Salmonella interaction
with host tumors.

Salmonella Behavior in the Tumor Environment
Two nonexclusive hypotheses have been proposed to explain Salmonella’s preference for
survival in malignant tumors. First, the anaerobic, necrotic, or highly vascular
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environments in and around tumors may provide bacteria with an advantageous niche for
growth [95]. Second, the bacteria may selectively replicate in tumors due to immune
protection. However, very little is known about whether the bacteria themselves behave
differently in response to cancer cells. In particular, it has not been determined how
neoplastic host cells, in contrast to normal (i.e., non-neoplastic) host cells, might
specifically trigger Salmonella gene expression. Neoplastic cells often exhibit notable
phenotypes, including alterations in cell cytoskeleton, signaling pathways, replication
patterns, or expression of surface or secreted proteins [96]. In theory, any of these host
cell factors might modify bacterial gene expression. Recent findings support the premise
that neoplastic tumors may well alter Salmonella’s behavior. For example, in an in vitro
tumor model system, Salmonella migrate toward and collect in cylindrical aggregates of
tumor cells [97, 98]. These findings raise the prospect that tumor cells release
compounds Salmonella can sense and travel toward. In another study, Salmonella
recovered from tumors in vivo were more efficient at subsequently attaching to, invading,
and replicating within colon adenocarcinoma cells in vitro than the parent strain [84]. The
fact that in vivo passage through a mouse tumor produced a Salmonella strain with an
enhanced tumor-targeting phenotype suggests that Salmonella can indeed be modified by
interactions with tumors. Perhaps these phenotypic changes reflect Salmonella gene
expression events involved in tumor localization, attachment and persistence.
The seemingly conflicting ideas of Salmonella as both pro-cancer and anti-cancer agent
leave the state of the field unclear. Work must be done to clarify how Salmonella
immunostimulatory activity may lead to cancer-causing environments and what effect
colonization of the tumor has on bacterial activity. The dynamic interplay between
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Salmonella and the host will inform development of future tumor and Salmonella
therapeutics.

1.5 Bioluminescence Imaging as Tool to Study Prokaryotes and
Eukaryotes
The points addressed above rely on gaining more information on Salmonella interactions
with its host on a global level. One powerful, emerging technique, bioluminescence
imaging (BLI), provides the reliability and throughput necessary to study Salmonella
behavior much more dynamically than ever before. BLI is based on the use of eukaryotic
or prokaryotic encoded luciferase enzymes that catalyze a reaction utilizing ATP,
oxygen, and a luciferin substrate to produce light. In eukaryotic systems, firefly
luciferase from Photinus pyralis is most commonly used [99]. Bioluminescently-tagged
tumor xenografts have provided a convenient and reliable way to monitor tumor
progression during therapeutic studies [99]. Also, eukaryotic luciferase can be coupled to
proteins of interest, and used in studies of signaling pathways, protein stability, and gene
transcriptional activity [99].
Several bacterial luciferases are also available, originally from the organisms Vibrio
harveyyi, Vibrio fischeri or Photorhabdus luminescens [100]. Unlike eukaryotic
luciferases, which generally require the addition of exogenous substrate for imaging, the
biosynthetic pathways for the bacterial luciferin substrate are relatively simple and a
single five gene operon is responsible for both the luciferase enzyme and substrate
production [100]. Studies of microorganisms in vivo are uniquely suited to BLI and
bacterial-based imaging strategies encompass in vivo, in vitro and in cellulo reporter
studies. This is evident especially when imaging bacterial infection models, since use of
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a bacterial lux operon allows for BLI in real time, without requiring administration of
exogenous substrate. Furthermore, traditional in vivo infection models have required host
sacrifice and enumeration of microorganisms from individual host organs to determine
the extent and kinetics of dissemination during infection. BLI provides a unique
opportunity to serially monitor infection in a single host over time, often resulting in
identification of new sites of replication and persistence within an infected animal [99].
Finally, in the investigation of bacteria as a potential diagnostic and treatment tool for
cancer, BLI has become a particularly popular technique. In such cases, bacterial
luciferase has allowed for imaging the localization of bacteria to a tumor in a mouse in
real time [99].

1.6 Conclusion of the Introduction
Salmonella Typhimurium is a well-studied human pathogen. Emerging from the wealth
of knowledge on Salmonella and its genetic tractability is the desire to use the pathogen
in new ways – namely, as a cancer diagnostic and therapeutic tool. However, Salmonella
is still a pathogen, and therefore may still produce dangerous consequences within hosts,
especially one that may be immunocompromised, such as cancer patients. The answer to
this challenge is not to abandon Salmonella-based treatment altogether, but to search for a
deeper understanding of Salmonella-host interactions. Salmonella may prove to be a
simple, cost-effective and robust tumor treatment technique, but will require further study
of how Salmonella and the host co-exist to better inform future options.
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1.7 Figures
Figure 1-1

Figure 1-1: The Pathogenesis of Salmonella Typhimurium
Salmonella Typhimurium utilizes two separate Type Three Secretion Systems (TTSS)
during invasion and pathogenesis of host cells. Initially, the SPI-1 TTSS induces host
actin filamentation, resulting in bacterial uptake. Intracellularly, the SPI-2 TTSS
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promotes bacterial survival and replication through futher host actin cytoskeletal
remodeling and SCV maintenance.
Adapted from: Ibarra J. A., Steele-Mortimer O. (2009). Salmonella-the ultimate
insider. Salmonella virulence factors that modulate intracellular survival. Cell
Microbiol. 11, 1579–1586.

22

Figure 1-2

Figure 1-2: Toll-Like Receptor Signaling
Eukaryotic Toll-like receptors respond to extracellular and intracellular foreign antigens,
resulting in signaling pathway activation and nuclear activation of pro-inflammatory
transcriptional programming.
Adapted from: http://www.cellsignal.com/reference/pathway/pdfs/Toll_Like.pdf
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CHAPTER 2
Stably Integrated luxCDABE for Assessment of
Salmonellae Invasion Kinetics
2.1 Abstract
Salmonella Typhimurium is a common cause of gastroenteritis in humans, and also
localizes to neoplastic tumors in animals. Invasion of specific eukaryotic cells is a key
mechanism of Salmonella interactions with host tissues. Early stages of gastrointestinal
cell invasion are mediated by a Salmonella type-three secretion system, powered by the
ATPase invC. The aim of this work was to characterize the invC-dependence of invasion
kinetics into disparate eukaryotic cells traditionally used as models of gut epithelium or
neoplasms. Thus, a nondestructive real-time assay was developed to report eukaryotic
cell invasion kinetics, using lux+ Salmonellae that contain chromosomally integrated
luxCDABE genes. Bioluminescence-based invasion assays using lux+ Salmonellae
exhibited inoculum dose-response correlation, distinguished invasion-competent from
invasion-incompetent Salmonellae, and discriminated relative Salmonellae invasiveness
in accordance with environmental conditions that induce invasion gene expression. In
standard gentamicin protection assays, bioluminescence from lux+ Salmonellae
correlated with recovery of colony forming units of internalized bacteria, and could be
visualized by bioluminescence microscopy. Furthermore, this assay distinguished
invasion-competent from invasion-incompetent bacteria independent of gentamicin
treatment in real time. Bioluminescence reported Salmonellae invasion of disparate
eukaryotic cell lines, including neoplastic melanoma, colon adenocarcinoma, and glioma

32

cell lines used in animal models of malignancy. In each case, Salmonella invasion of
eukaryotic cells was invC dependent.

2.2 Introduction
Eukaryotic cell invasion is utilized by Salmonellae during initial steps of pathogenesis
(1), and leads to enteric symptoms and disseminated infection. Salmonellae also localize
to, and sometimes invade, cancerous tumors in mice (2). One basic tool for dissecting the
mechanisms of these bacterial-eukaryotic cell interactions is the in vitro cell invasion
assay.

The standard technique to assess Salmonella invasion into cultured cells is the gentamicin
protection assay (3), which exploits the poor penetration of this antibiotic into eukaryotic
cells (4). Specifically, gentamicin is postulated to kill susceptible extracellular bacteria,
but not “protected” bacteria that have invaded. Presumably, such selective killing permits
the preferential recovery of intracellular bacteria on subsequent culture of lysed cells.
Gentamicin protection assays have been used to illuminate genetic and cellular
mechanisms of cell invasion by Salmonellae (5). For example, the invC gene in
Salmonella encodes an ATPase that powers a type-three secretion system, triggering
eukaryotic actin reorganization and Salmonella invasion of some eukaryotic cell lines (6,
7).

Despite their widespread use, standard gentamicin protection assays are technically and
conceptually limited, because they attempt to quantify the invasiveness of individual
bacterial strains via direct enumeration of bacterial colony forming units recovered from
lysed eukaryotic cells. The lysis and colony forming unit (CFU) determination steps
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consume time, materials and labor. Colonies are not necessarily correlated with bacterial
numbers, so agglomerated organisms might be under-enumerated. Additionally, because
eukaryotic cells must be destroyed to release invaded bacteria, serial evaluations of
bacterial invasion in a single temporal assay are precluded. Furthermore, by definition,
current gentamicin-protection, CFU-based assays of invasion require that extracellular
bacteria of interest are killed by gentamicin, which is a condition not always met.

To attempt to address such limitations, we have modified current gentamicin protection
assays of bacterial invasion into eukaryotic cells, including neoplastic lines, by using
bioluminescence to report bacterial invasion. Contag et al. originally pioneered the use
of bacteria expressing luciferase to monitor in vitro and in vivo pathogenesis with
organisms containing plasmid-encoded luciferase (8). Here, we employ constitutively
bioluminescent Salmonellae, which contain chromosomally integrated luxCDABE genes
from Photorhabdus luminescens (9), and imaging systems that sensitively and
specifically detect bioluminescent Salmonellae (10). This nondestructive assay requires
neither eukaryotic cell lysis, nor gentamicin. Rather, we use bioluminescence to track the
invasion of lux+ Salmonellae into various eukaryotic cells in tissue culture. These
eukaryotic cells include those traditionally used for models of gastroenteritis, as well as
cells previously used in whole mouse models of metastatic cancers. To determine the
invC dependence of invasion kinetics in these different systems, we compare the
invasiveness of lux+ Salmonellae that are isogenic except for invC.
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2.3 Methods
Bacterial Strains and Eukaryotic Cell Lines: The bacterial strains and eukaryotic cell
lines used in this study are listed in Table 2-1.

Construction of Salmonellae Strains with Stably Integrated: luxCDABE Conjugative
mating was performed between donor strain E. coli S17-1 (containing the transfer
plasmid pUT mini-Tn5 lux Km2; gift of Michael Winson), and recipient Salmonella
enterica serovar Typhimurium strain SB300A1 (11). Mating was performed as described
(12) in Luria-Bertani (LB) broth, then plated onto LB agar, and incubated at 37oC
overnight. Mated colonies were scraped from the LB agar, and onto kanamycin (50
µg/mL) MacConkey agar to discriminate Salmonellae from E. coli. The isolated
candidate Salmonellae were grown at dilutions of 10-5, 10-6, and 10-7 on these agar plates
for 48 hours. Replating on LB/kanamycin plates documented the kanamycin resistance of
the recipients of pUT mini-Tn5 lux Km2. PCR confirmed the gross presence of each
gene of luxCDABE in the new strains, but not in the parent Salmonella SB300A1.

Identification of Site of luxCDABE Integration into the Salmonella Genome: First, the
general location of luxCDABE integration was determined from sequences of amplicons
produced using touchdown PCR (13) of the genomic DNA of our new lux+ Salmonella
strain. Touchdown PCR used high fidelity Taq DNA polymerase (Invitrogen), and
thermal cycling conditions (95oC for 5 minutes; then 25 cycles of 95oC for 45 seconds,
annealing at variable temperature for 45 seconds (60oC in the first cycle and, at each of
the 24 cycles, decreased by 0.5oC per cycle down to 47.5oC), and extension at 72oC for 2
minutes). This was followed by 25 cycles of 95oC for 45 seconds, 50oC for 45 seconds,
and 72oC for 2 minutes. Primer pairs included a degenerate primer
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CCGAATTCCGGATNGAYKSNGGNTC (where N=A, C, G, or T; Y=C or T; K=G or
T; and S=C or G), in combination with either an outward facing luxC or luxE primer
(outward luxC: CCATCTTTGCCCTACCGTATAGAG and outward luxE:
TGAGGATGAAATGCAGCGTA). Sequence data from the resulting amplicons
suggested luxCDABE integration between Salmonella chromosomal genes acrB and hha.

The precise integration site of luxCDABE was then identified. PCR amplification from
the genomic DNA of our new lux+ Salmonella strain was performed using two sets of
primers. One reaction, which produced an amplicon of approximately 2.5kb, used luxE
(TGAGGATGAAATGCAGCGTA) and hha (GCCAGAACGAGGAGGCAGATAACA)
primers, and PCR conditions of 94oC for 3 minutes; 30 cycles of 94oC for 30 seconds,
51oC for 30 seconds, 72oC for 3 minutes; and 72oC for 7 minutes. The second reaction
produced an amplicon of approximately 3kb, with luxC
(ATCCAATTGGCCTCTAGCTTAGCC) and acrB (ACCTCAACGGATGAGTTTGG)
primers, and PCR conditions directly above. These amplicons above were sequenced by
the Protein and Nucleic Acid Chemistry Laboratory at Washington University in St.
Louis. Sequences were aligned with the Salmonella enterica serovar Typhimurium strain
LT2 complete genome sequence (14).

Growth Curves in Liquid Culture: Otherwise isogenic Salmonellae with and without
chromosomal luxCDABE were grown in overnight liquid cultures then diluted 1:10 into
fresh liquid media for growth curve analysis. Growth was assessed via serial optical
transmission measurements. For growth curve analyses, growth media was Luria-Bertani
(LB) broth, and incubation was at 37oC in a shaker incubator at 200-250 rpm.
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Construction of an In-frame invC Deletion Mutant of luxCDABE+ Salmonella: An inframe excision of invC nucleotides between 506 and 590 was performed using the
pCVD442 suicide vector, engineered as previously described (15), for gene allele
exchange (16). Here, 5’ and 3’ segments of invC were amplified from wild-type invC+
Salmonella SB300A1 (11) by PCR using the respective primer pairs
5′GGAGCGAGCTCACTGCAATATCTGGCCTACCCACA3′ with
5′GGAGCAAGCTTATCAGCATGGTCTTACCGCATCCT3′; and
5′GGAGCAAGCTTGGATATGTTGCGCGCTTCGCATAA3′ with
5′GCTATCTCGAGTTTCGCCAGGACGATATTCTCCCA3′. These four primers
contain SacI, HindIII, HindIII, and XhoI sites, respectively, and nucleotides (underlined,
above) of the published Salmonella LT2 genomic sequence for invC (14). The resulting
PCR products were digested with SacI and HindIII, or with HindIII and XhoI,
respectively; then individually cloned into pBSIISK+. Following digestion of these two
plasmids with SacI and HindIII, or with HindIII and XhoI, respectively, the small
fragments were cloned in tandem into SacI and XhoI digested pBSIISK+, producing
pBSIISK+(invCΔ506-590). Finally, the SacI delimited insert of pBSIISK+(invCΔ506590) was ligated into SacI linearized suicide plasmid pCVD442 (16). The resulting
pCVD442(invCΔ506-590) was transformed into E. coli SM10(λpir) (17). Mating was
performed between the donor SM10(λpir) strain and the bioluminescent chromosomal
luxCDABE+ Salmonella strain SB300A1FL6 on LB agar. The cells were then scraped
from the LB plates and serial dilutions (to 10-7) were made in LB. 100 µL of the dilutions
were spread on MacConkey agar containing ampicillin (100 µg/mL) and kanamycin (50
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µg/mL) to select merodiploids. Of 30 merodiploid candidates, five were picked and
grown overnight in LB media without salt. These cultures were then plated on 5%
sucrose plates and incubated overnight at 30oC to select for sacB removal. Presumptive
sacB deficient colonies on sucrose plates were further screened on LB ampicillin (100
µg/mL) plates for a phenotype consistent with concomitant excision of the bla gene. One
such ampicillin susceptible clone was analyzed by PCR amplification using invC flanking
primers. The resulting amplicon was sequenced, to confirm the anticipated 84 nucleotides
deletion from the 1296 nucleotide long invC, between invC nucleotides 506 and 590. The
invC mutant also includes a six nucleotide HindIII site introduced as a byproduct of
subcloning steps above (i.e., TGCTGATAAGCTTGGATAT, with invC nucleotides 506T
and 590G underlined). Accordingly, the predicted InvC protein encoded by our invC
mutation is missing intact InvC amino acids 169 to 197, and has an isoleucine-serineleucine insert encoded by the TAA/GCT/TGG sequence created by the HindIII site insert.
This invC mutant does not create a frame shift; so should not have polar effects on
adjacent genes.

Invasion Assays: Standard gentamicin-protection assays were performed as described
(18). Salmonellae grown overnight in LB broth (37oC) were diluted 1:100 or 1:10 and
grown to an OD 600 of between 0.45 and 0.7, with OD 600 matched across samples for a
given experiment. Incubations were not shaken, except where noted, and as previously
described (19). These bacteria were diluted 1:10 in DMEM, or to a multiplicity of
infection of 100 where noted.
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Diluted bacterial suspensions were added to tissue culture plates, at 500 µL to each well
in 24 well plates, or 100 µL to each well in 96 well plates. For 60 minutes, the bacteria
were coincubated with adherent tissue culture monolayers at 60 to100% confluence.
Wells were then washed with DMEM and treated with media containing gentamicin at a
final concentration of 100 µg/mL. The antibiotic-containing media was replaced with
phenol-red free media after 90 minutes of treatment and bioluminescence was measured
three and a half hours later (five hours after the initiation of gentamicin treatment), unless
otherwise noted. Gentamicin-free conditions represented use of phenol-red free DMEM
lacking gentamicin after the wash step; imaging occurred three hours after washing.

In the CFU recovery assay, following bioluminescence imaging, bacteria were quantified
by CFU recovery after immediate lysis of tissue culture cells with detergent lysis as
described (McKinney et al., 2004).

Measurement of Bioluminescence: Bioluminescence measurements were performed as
published (20-22). Images were captured with a cooled CCD camera (IVIS 100, Caliper,
Hopkinton, MA). Acquisition parameters were: exposure time, 30s; binning, 8; no filter;
f/stop, 1; FOV, 15 cm. Signals were measured as the radiance (photons/second/cm2/sr).
To calculate the bioluminescence from a given well, total photon flux (photons/second)
was determined from a region-of-interest (ROI) positioned over the given well and an
empty well, which was subtracted to correct for background machine noise using Living
Image (Xenogen) and Igor Pro (WaveMetrics) Software. Bioluminescence was presented
as mean ± standard deviation of the mean of the total photon flux for replicate well
assays.
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Bioluminescence Microscopy: Henle cell monolayers cultured on glass bottom 35 mm
dishes, with or without luxCDABE+ Salmonellae, were treated as described for
gentamicin protection invasion assays. Two to three hours after Salmonellae inoculation,
these plates were examined on an inverted microscope (Nikon TE 2000-S) housed in a
light tight microscope incubator (In Vivo Scientific) with temperature maintained at
36ºC. Bioluminescence was recorded with a cooled intensified CCD camera
(XR/MEGA10-AW, Stanford Photonics) controlled by Piper Imaging software version
1.3.6 (Agile Automation). Due to high amplification of the signal (gain set at 400,000),
camera noise was reduced during image acquisition by setting a minimum threshold for
the signal that was kept constant for all cultures. Fifteen image sequence frames were
obtained per second and integrated later in 40 min stacks to obtain a single image.
Integration, pseudo-color processing and color merge were performed with ImageJ
(National Institutes of Health, USA) and Photoshop CS2 (Adobe) software.

2.4 Results
Chromosomal Integration of luxCDABE To create a Salmonella strain that
constitutively produced bioluminescence, a Tn5 transfer plasmid was used to engineer a
strain with chromosomal integration of the luxCDABE operon without disrupting
essential genes in this process. Independent PCR assays, followed by amplicon DNA
sequencing, defined the luxCDABE integration site in the Salmonella chromosome
(Figure 2-1). According to Salmonella strain LT2 complete genomic sequence
annotation convention (14), luxCDABE in our Salmonella integrated at nucleotide
528,771, twenty nucleotides 5’ to the start codon of ybaJ.
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Despite some preference for insertion at G/C pairs (23), Tn5 is considered to mediate
near-random integration into bacterial genomes (24). Interestingly, in bioluminescent
Salmonellae produced by another laboratory using the same suicide vector system, the
transposon is reported to have integrated at hha (25). Given that hha is immediately 3’ to
ybaJ in the Salmonella genome, perhaps there is preferential integration of the Tn5
luxCDABE element into the Salmonella genome near ybaJ / hha.

Alterations in hha gene expression, secondary to luxCDABE integration, in principle
could alter pathogenesis, because Hha negatively regulates hilA (26), and hilA regulates
the invasive phenotype of Salmonellae (27). However, our new luxCDABE+ Salmonella
does not exhibit decreased hha mRNA levels, assessed by RT-PCR, compared to its
parent (data not shown).

Fitness and bioluminescence of luxCDABE+ Salmonellae The growth curves of
otherwise isogenic Salmonellae with and without luxCDABE were identical in LB broth
(data not shown). As predicted, the Km2 kanamycin selection marker integrated with
luxCDABE did not bestow resistance to gentamicin at concentrations of 100 µg/mL (data
not shown). Furthermore, the kanamycin resistance and bioluminescence phenotypes of
our luxCDABE+ Salmonellae were stably maintained without kanamycin selection, both
in long term in vitro cultures and in mouse infections (data not shown).

Invasion Competence of luxCDABE+ Salmonellae To determine the impact of
integrated luxCDABE on Salmonella invasiveness, we performed parallel standard
gentamicin protection assays with equal inoculations of otherwise isogenic Salmonellae,
differing only in the presence or absence of chromosomally integrated luxCDABE. Based
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on numbers of bacterial colony forming units from lysed eukaryotic cells, there was no
defect in Salmonella invasion because of luxCDABE integration (data not shown).

Bioluminescence as a Reporter of Invasion by luxCDABE+ Salmonellae As
determinates of host cell invasion, we compared Salmonellae bioluminescence assays and
colony forming units (CFU) from standard gentamicin invasion assays in tissue culture
wells. Following measurement of bioluminescence signals from invasion assay tissue
culture wells, we processed the tissue culture wells to obtain CFU data from the same
assay wells that had been imaged for bioluminescence. We lysed the eukaryotic cells
and used plate counts to recover and enumerate Salmonellae CFU. There was
concordance between bioluminescence output and CFU recovery in gentamicin
protection assays (Figure 2-2). Furthermore, bioluminescence readily discriminated
between invasion-competent and invasion-incompetent luxCDABE+ Salmonellae strains.
The protein encoded by invC is an ATPase that powers a type-three secretion system,
triggering eukaryotic actin reorganization and Salmonella invasion (6, 7).
Bioluminescence distinguished between otherwise isogenic chromosomal luxCDABE+
Salmonellae strains that had an invC gene that was either intact (invC+), or ablated by an
in-frame deletion (invC-) (Figure 2-2). Our invC- strain is more than 200-fold less
invasive compared with isogenic invC+ Salmonella concordantly assessed by standard
gentamicin protection assay (6, 7, 18).

Salmonella invasiveness can also be modified by varying environmental conditions. For
example, entry into eukaryotic cells can be significantly enhanced when invasion
competent Salmonellae are prepared using standing rather than shaken cultures (19).
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Using a bioluminescence-based gentamicin protection assay, we could discriminate these
invasion phenotype differences for invC+ Salmonellae that differ only in culture
conditions prior to exposure to eukaryotic cells (Figure 2-3). By contrast, the otherwise
isogenic invC- Salmonella remained minimally invasive when prepared in either standing
or shaken cultures (Figure 2-3).

We reproducibly observed bioluminescence enhancement with increasing Salmonella
inoculum (Figure 2-4). In standard gentamicin protection assays, the multiplicity of
infection often requires optimization (3). In the bioluminescence assay, we detected wild
type Salmonella invasion into eukaryotic cells over a twenty-fold range in multiplicity of
infection (Figure 2-4).

Salmonella Invasion into Diverse Eukaryotic Cells: Dependence on invC
Salmonellae often invade eukaryotic cells postulated to be relevant to cell-cell
interactions during pathologic intestinal infections (e.g., Henle intestinal epithelial cells
(3), HT29 colon carcinoma cells (28)). Salmonellae also localize to cancerous tumors in
animals (2, 29, 30), including non-intestinal cells, such as melanoma, glioma, breast and
prostate neoplastic cells. Salmonellae can be recovered from these tumors, and in some
cases appear by electron microscopy to have invaded the neoplastic cells (2). Here, we
examined the ability of Salmonellae to invade various cells used for models of
malignancy in mice. Our wild type bioluminescent Salmonella invaded not only Henle
(Figure 2-2) and HT29 colon cells, but also eukaryotic cells of diverse origins, including
colon adenocarcinoma MC38, melanoma B16F10 and even, albeit to a lesser extent,
glioma C6 cells. In each case, this invasion depended on invC (Figure 2-5).
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Real-Time Kinetic Measurements of Bioluminescence During Invasion Assays The
nondestructive nature of bioluminescence now permits serial assessments of the same
invaded cells over time. We assessed the kinetics of Salmonella bioluminescence from
single wells of C6 glioma cells during invasion assays. The bioluminescence from a
given well reflects several factors, including Salmonella cell numbers and viability. At a
given time, Salmonella viability is influenced by the effects of gentamicin and the
protection from gentamicin killing afforded by Salmonella invasion into eukaryotic cells.
Bioluminescence versus time is shown in Figure 2-6. In this experiment, the distinction
between bioluminescence of invC+ versus invC- Salmonellae was most pronounced five
hours after initial inoculation.

Salmonella Invasion Assay, With and Without Gentamicin Protection Our ability to
distinguish invasion-competent from invasion-incompetent Salmonellae at time points
soon after adding gentamicin (Figure 2-6) raised the possibility that bioluminescence
could assess invasion independent of gentamicin protection per se. Accordingly, rather
than gentamicin treatment, we employed a washing step with three rounds of gentamicinfree media to physically deplete noninvaded Salmonella from the assay wells. In assays
in which gentamicin was not used, invC-dependent invasion competence of Salmonellae
could still be readily resolved (Figure 2-7). While overall assay time was shorter, the
background activity was higher.

Bioluminescent Salmonellae Visualized by Cooled CCD Microscopy. Traditionally,
bioluminescent bacteria have been most extensively exploited for imaging studies of
bacterial spread within whole animals, such as for Salmonellae infections manifesting as
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gastroenteritis or disseminated infections (8, 25), or for the targeted localization of
Salmonellae to malignant tumors (29). By contrast, for microscopic level studies of
bacterial localization (30) or gene expression (31), fluorescent rather than bioluminescent
bacteria have been most widely used. Given recent advances in cooled CCD cameras and
our interest in tracking luxCDABE Salmonellae microscopically, we attempted to
visualize our luxCDABE+ Salmonellae using a cooled CCD bioluminescence
microscope. Compared to uninfected eukaryotic cell controls, tissue cultures inoculated
with luxCDABE+ Salmonellae with intact invC exhibited foci of bioluminescence, with
maximal intensity foci clustered near or within eukaryotic cells (Figure 2-8). For
luxCDABE+ Salmonellae lacking invC, the number and intensity of these foci at the
single cell level were much reduced (data not shown). The ability to use microscopy to
visualize invasion by our bioluminescent Salmonellae provides an additional advantage
as bioluminescent microscopy does not require potentially cytotoxic excitation light and
typically has low background signal.

2.5 Discussion
We report a new constitutively bioluminescent Salmonella strain (SB300A1FL6). We
have subsequently deleted (in frame) specific segments of invasion competence genes in
this primary luxCDABE+ Salmonella strain, creating a set of reagents to study the
functions of specific Salmonella genes during bacterial-host interactions. In our
Salmonellae clones, luxCDABE was apparently maintained at low fitness cost. This
contrasts with other Salmonellae strains that have been engineered to be constitutively
fluorescent via the presence of green fluorescent protein. For example, green fluorescent
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proteins can significantly inhibit Salmonella growth in epithelial cells and macrophages
(32), and increase Salmonella doubling time (33).

Plasmid-based lux constructs have been exploited as reporter systems for bacterial
location in vitro and in vivo (8, 29). However, plasmid-based lux systems can suffer from
instability. Using the pLITE lux expression plasmid in Salmonella infections of mice, loss
rates of plasmid (and bioluminescence) exceeding 95% of bacterial colonies have been
reported (29). We observed no loss of bioluminescence of our chromosomal
luxCDABE+ Salmonellae strains after serial passages in bacterial cultures or after
prolonged infections in mice, even in the absence of kanamycin selection to maintain the
luxCDABE / kanamycin resistance gene insert.

One motivation for constructing and characterizing these luxCDABE+ Salmonellae
strains was to use bioluminescence to assess Salmonellae invasion kinetics into
eukaryotic cells. Herein, we described a robust and versatile eukaryotic cell invasion
assay using chromosomal luxCDABE+ Salmonellae. The new assay correlated well with
the standard detection methodology over a broad inoculum range. The bioluminescence
assay readily discriminated the invasion competencies of invC+ and invC- Salmonella.
Indeed, the resolution between invC+ and invC- organisms was reliable across a twentyfold range of bacterial inoculated dose and multiplicities of infection. By contrast, CFUbased assays are notably non-linear with respect to the number of inoculated bacteria (3).
Bioluminescence-based invasion assays also resolved invasion differences among lux+
Salmonellae as regulated by environmental stimuli (19).
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Bioluminescence-based tracking of lux+ Salmonellae during eukaryotic cell invasion
permits invasion assays to be performed independent of the stringent requirements of
gentamicin protection assays. For example, bioluminescence assays need not depend on
the use of gentamicin to kill extracellular bacteria, or eukaryotic cell lysis to report
intracellular “gentamicin-protected” bacteria. This allows studies on bacteria intrinsically
resistant to gentamicin or enables analysis in growth conditions that compromise
gentamicin activity (e.g., acidic pH or divalent cation concentrations (34)), as while also
allowing assays in which gentamicin-mediated effects on eukaryotic phenotypes are a
concern (35, 36).

Our assay had similarities to other techniques for assessing bacterial invasion, such as
direct observation of internalized bacteria following Giemsa staining (37), or direct
observation of gfp labeled bacteria within eukaryotic cells via fluorescent microscopy
(30) or FACS analysis (31). However, luxCDABE encoded bioluminescence provided
potential advantages to detect intracellular bacteria. For example, in contrast to Giemsa
staining of inanimate features of bacterial cell walls, or to gfp based fluorescence, lux
bioluminescence only reported bacteria that were alive and biochemically active (38).
This direct detection of living bacteria removed the lag time and intermediate maneuvers
imposed by experiments that rely on bacterial staining or recovery of bacterial CFUs for
data. The real-time and non-destructive nature of lux-based tracking of Salmonellae in
eukaryotic cells also allowed serial measurements from the same well over time. Hence,
it was well-suited to kinetic studies of bacterial invasion and intracellular survival. From
a technical perspective, bioluminescence-based detection of lux+ Salmonellae should
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readily allow high throughput experimental scaling in multiwell plate assays, with
readout times within minutes.

Furthermore, the components of the experimental system described here for studying
bacterial invasion into eukaryotic cells in tissue cultures can also be used to
noninvasively detect and localize luxCDABE+ Salmonellae during infections in living
mice (data not shown). Thus, bioluminescence-based detection of lux+ Salmonellae
presents opportunities to more directly correlate in vitro and in vivo models of bacterialhost interactions. This can be used to detect Salmonellae in experimental mouse models
of infection and malignancy. Intriguingly, our bioluminescent Salmonellae invade a
disparate range of malignant eukaryotic cells in vitro, each in an invC-dependent manner.
This suggests that Salmonellae interactions with eukaryotic neoplastic cells may
recapitulate features of Salmonellae interactions with eukaryotic epithelial cells in the
host intestinal tract.
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2.7 Tables
Table 2-1: Strains and eukaryotic cell lines used in the study
Strain or Cell Line Description

Source or
reference

Salmonella

Parent Strain, not bioluminescent. Contains araC-

Reference

SB300A1

P BAD regulated T7 RNA polymerase.

(11)

Salmonella

SB300A1, modified by chromosomal integration of

This study

SB300A1FL6

luxCDABE to be constitutively bioluminescent

Salmonella

SB300A1FL6, modified by in-frame excision of

This study

SB300A1FL6AM1 invC nucleotides between 506 and 590
E. coli

Donor strain in conjugation with SB300A1, for

Reference

S17-1

delivery of pUT mini-Tn5 lux Km2

(12)

E. coli SM10(λpir)

Donor strain in conjugation with SB300A1FL6, for

Reference

delivery of plasmid pCVD442(invC506-590)

(17)

Human epithelial cell line

ATCC:

Henle 407

CCL-6
B16F10

Murine melanoma cell line

ATCC:
CRL-6475

HT29

Human colon carcinoma cell line

ATCC:
HTB-38

C6

Rat glioma cell line

ATCC:
CCL-107

MC38

Murine colon adenocarcinoma cell line

Gift: N.O.
Davidson
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2.8 Figures
Figure 2-1

Figure 2-1: Foreign DNA integration site into Salmonella genome, at nucleotide
528,771. Nearby loci are acrB, ybaJ, and hha, flanking the insert site of luxCDABE and
Km2 as shown. The following DNA sequence from the chromosome of our
bioluminescent Salmonella identifies the junction between Salmonella genomic DNA
(non-italics, corresponding to Salmonella LT2 genome nucleotides 529,230 to 528,771)
and foreign DNA (italics, with luxC coding nucleotides 1-163 in underlined italics):
AAGGCCGCGCAAGCGGCCTTTTTTACGCAAAAATCATAAAATACGCTTAT
TGTTAGATTGATTATTTTTTGCCATATTAATAAAAGGTATAATCCTTACTG
CGTTAAAGGCTTTTCTTAGGAAAGTTGGCCATTTCTTAATTCAGCCATTA
ATTAAGAAATATTAAGAATATTCCTGGCTATTTTCTCCTGTCAGAGTCTA
TTGTTTTAGCCTGAAAAGCTAAAAAACGTTAACCCAATGATTACACAAAC
AATAAAACTGGTTCCTTTTTAGGCGACCGACGATCACTGTTAAAATTCGA
AAAAGTATGGCAACACGCGGCTTTCACGCAATTGTAATTTTTAGTAATAT
GACGATGAAAAGTTTTTTAGAGTAGATTATAGTTAAATCATAAGGTGACG
TGGGAAGTACCAGGTTAGTTAGTTGTATCCATCCCGAAGGTGTTCGGTT
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AGTTTAAGCCCTGACTCTTATACACAAGTGCGGCCGCGTTTAAACCCATGGACGT
GTTGACAATTAATCATCGGCATAGTATATCGGCATAGTATAATACGACTCAGGGCC
CACTAGTGGTACCCGGGGATCCTCTAGAGTCGACCTGCAGGTCGACGGATCCGG
GGAATTCAGGCTTGGAGGATACGTATGACTAAAAAAATTTCATTCATTATTAACGGC
CAGGTTGAAATCTTTCCCGAAGGTGATGATTTAGTGCAATCCATTAATTTTGGTGAT
AATAGTGTTTACCTGCCAATATTGAATGACTCTCATGTAAAAAACCATTATTGATTGT
AATGGAAATAACGAA
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Figure 2-2

Figure 2-2: Comparison of colony forming unit (CFU) recovery and
bioluminescence (photon flux, in photons/second) from gentamicin protection assays
using bioluminescent Salmonellae that vary only by invC gene status. Data from a
representative gentamicin protection assay performed in triplicate wells are shown. Here,
invasion of Henle epithelial eukaryotic cells was assessed by bioluminescent Salmonellae
either with invC (wild type, invC+) or without invC (invC-). In each case the multiplicity
of infection was 100. CFUs report Salmonellae grown from lysates, per single wells in a
24 well plate. Photon flux is in units of photons/second, also per single wells in a 24 well
plate. CFU and photon flux results are shown as means (+/- SD). A representative pair of
wells from the bioluminescence-based assay is shown with adjacent wells containing
either invC+ (left well) or invC- (right well) luxCDABE+ Salmonellae; the pseudo-color
scale denotes photon intensity radiance. Similar results were obtained in experiments
using HT29, rather than Henle eukaryotic cells (Figure 2-5 and data not shown).
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Figure 2-3

Figure 2-3. Bioluminescence and gentamicin protection following differing
Salmonella growth conditions known to induce enhanced Salmonella invasiveness.
The bar graph compares bioluminescence data obtained from a bacterial invasion assay of
HT29 eukaryotic cells by bacteria previously grown in cultures that were either shaken or
standing. Standing cultures are known to induce enhanced Salmonella invasiveness in
cell culture, as compared with shaken culture conditions (19). Induction state is as
indicated. Photon flux data are shown as means (+/- SD), in units of photons/second, and
were obtained 90 minutes after adding gentamicin.
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Figure 2-4

Figure 2-4. Bioluminescence signal intensity correlated with Salmonella inoculum
dose. Photon flux signals from invasion assays of HT29 cells across a 20-fold dilution
range of invasion competent (invC+) bioluminescent Salmonella. Because eukaryotic
cell numbers per well were constant, this also corresponds to 20-fold range of multiplicity
of infection. In wells lacking eukaryotic cells, photon flux signals approach ambient
background. Results are from quadruplicate samples, with photon flux data (in units of
photons/second) shown as means (+/- SD).
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Figure 2-5

Figure 2-5. Invasion of bioluminescent Salmonellae into eukaryotic cell lines of
diverse origins. Photon flux data represent invasion of wild type invC+ and invCSalmonellae into human intestinal HT29, mouse colon adenocarcinoma MC38, mouse
melanoma B16F10 or rat glioma C6 cell lines. For invC+ bioluminescent Salmonellae,
the photon signal following exposure to glioma eukaryotic cells was approximately onetenth that seen with adenocarcinoma cells (note different y-axis scale for glioma cells).
Data are from triplicate wells, shown as means (+/- SD), in photons/second.
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Figure 2-6

Figure 2-6. Kinetics of bioluminescence during Salmonellae infection. Photon flux
data of bacteria serially measured from the same invasion assay wells. The times
indicated hours after initiation of a 90 minute gentamicin treatment followed by
replacement with media. Salmonellae invC+ and invC- strains, and C6 glioma eukaryotic
cells, are as described above. Data are from triplicate wells, shown as means (+/- SD), in
units of photons/second.
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Figure 2-7

Figure 2-7. Bioluminescence monitoring of Salmonella interactions with eukaryotic
cells, using gentamicin-containing and gentamicin-free media. Photon output from
invC+ and invC- Salmonellae invasion of Henle cells, from quadruplicate samples, with
photon flux data shown in units of photons/second, expressed as means (+/- SD).
Gentamicin-treatment conditions represented 90 minutes of gentamicin incubation,
following replacement with phenol-red free DMEM media, and imaging at 5 hours after
initiating gentamicin addition. Gentamicin-free conditions represented use of phenol-red
free DMEM media lacking gentamicin throughout, followed by three washes; imaging
occurred three hours after washing.
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Figure 2-8

Figure 2-8. Microscopic detection of bioluminescence from luxCDABE+ Salmonella
in eukaryotic cell cultures. Henle cell monolayers are shown either alone (left panels)
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or following inoculation with luxCDABE invC+ Salmonella (right panels). For each
sample, images show the bioluminescence signal alone (top), the phase contrast (bottom),
and a merged image of bioluminescence and phase contrast (middle). Within the merged
image of the Henle cells inoculated with luxCDABE Salmonella, a box demarcates the
image area enlarged in the upper right corner (inset). Yellow arrows outline a Henle cell;
maximal intensity foci occur near or within eukaryotic cells. Spectral scales denote
pseudo-color representation of bioluminescence signal intensity in relative light units
(RLU), ranging from 1 to 50 RLU for samples without Salmonella, and 1 to 100 RLU for
samples with Salmonella. Processing of these samples followed the same methods as
gentamicin protection assays described in the text; images were obtained two to three
hours after inoculation of Salmonella. Bar = 50µM.
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CHAPTER 3

Cancer Cell–Induced Transcriptional Response of
Salmonella Typhimurium Visualized with a
Bioluminescent Transposon Reporter-Trap
3.1 Abstract
Salmonella specifically localize to malignant tumors in vivo, a trait potentially exploitable
as a cancer drug delivery system. To characterize mechanisms and genetic responses
of Salmonella during interaction with living neoplastic cells, we custom designed a
promoterless transposon reporter containing bacterial luciferase. Analysis of 7,400
independent Salmonella transposon insertion mutants in co-culture with melanoma or
colon carcinoma cells identified five bacterial genes specifically activated by cancer cells,
adiY, yohJ, STM1787, STM1791, and STM1793. Further experiments identified acidic
pH, a common characteristic of the tumor microenvironment, to be a strong, specific and
reversible stimulus for Salmonella gene activation in vivo and in vitro. Finally, a
Salmonella reporter strain expressing a plasmid encoding the luciferase transgene driven
by the STM1787-inducible promoter showed tumor-mediated transgene activation in vivo,
demonstrating the potential for a new bacterial-based cancer therapeutic. Salmonella,
which often encounter acidic environments during classical host infection, may co-opt
evolutionarily conserved pathways for tumor colonization in response to the acidic tumor
microenvironment. Therefore, specific promoter sequences may provide a platform for
Salmonella-based tumor therapy with two inherent levels of target specificity in vivo.
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3.2 Introduction
Salmonella Typhimurium is a Gram-negative bacterium and a common human
gastrointestinal pathogen. In human hosts, the organism is typically acquired by ingestion
of bacteria causing a gastroenteritis that may progress to a systemic infection. Salmonella
Typhimurium, characterized by its ability to invade host cells, utilizes genes from two
chromosomally-encoded pathogenicity islands, SPI-1 and SPI-2, which contain genes
encoding two separate type-three secretion apparatuses, as well as suites of effector genes
and various transcription regulators. Research has uncovered important functions during
both cell invasion and disease pathogenesis for many of these virulence genes.

Recently, new research has indicated that Salmonella, in addition to its ability to cause
gastrointestinal disease, may be utilized as a potential diagnostic or therapeutic reagent
for malignant tumors. Using bioluminescent and fluorescent bacteria, previous research
has shown that intravenously delivered Salmonella are remarkably capable of localizing
to and persisting within xenograft tumor models in vivo [1]. The ability of Salmonella to
localize to tumors is impressive, as it has been shown that Salmonella bacteria are
capable of colonizing and persisting in tumors at rates 10,000 times greater than
colonization of other organs [2]. Salmonella localize both to metastases and tumors, and
show specific replication in tumors for weeks in vivo [1, 3]. Studies have also utilized the
genetic tractability of the organism to design strains that cause little widespread damage
to their hosts while retaining the ability to target and persist within tumors [3, 4].

At least two popular hypotheses are proposed to describe the Salmonella tumor-targeting
phenotype. The first assumes tumors are a relatively immunoprotected site within a host
animal, and bacteria may survive specifically in the privileged microenvironment of the
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tumor, whereas in other normal tissues are cleared by the host’s immune system. The
second hypothesis proposes that bacteria are attracted by chemotactic factors to a necrotic
environment wherein the availability of excess nutrients in the tumor facilitates
replication within this site. To this end, Kasinskas, et al., has shown that bacteria tend to
accumulate in specific regions of an in vitro tumor model and this behavior is based on
nutrient sensors and the chemotaxis machinery [5, 6].

Compared to investigations of the Salmonella pathogenic cycle, few experiments have
investigated the specific genetic responses of Salmonella to eukaryotic tumor cells and
bacterial mechanisms regulating this unusual and interesting detour from the typical
disease route. In the present work, we engineered a bioluminescent transposon reportertrap to screen a Salmonella Typhimurium library for genes specifically regulated by coculture with malignant cells in vitro. Five genes were identified by the screen and their
promoter sequences were found to be specifically activated by the acidic
microenvironment associated with cancer cells in vitro and tumors in vivo. Finally, we
utilized one of the activated promoter sequences to demonstrate proof-of-principle studies
of Salmonella-based tumor therapy with two inherent levels of target specificity in vivo.

3.3 Methods
Bacterial strains and culture conditions: The Salmonella typhimurium strains SB300A1
[7], SB300A1FL6 (luxCDABE) [8], luxAB and AM3 (luxCDABE msbB-) were grown in
LB broth with appropriate antibiotics. SB300A1FL6 is modified by chromosomal
integration of luxCDABE and is constitutively bioluminescent. The luxAB strain consists
of SB300A1FL6 with the integrated luxE gene disrupted. This strain does not
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bioluminesce without addition of exogenous decanal substrate. The AM3 strain has the
SB300A1FL6 background, but also has an msbB gene disruption, giving it a less
immunogenic LPS structure. The Tn:27.8 strain, specifically identified from the screen as
a non-inducible mutant, phenocopies luxAB with constitutive bioluminescence that
requires exogenous decanal.

Tissue culture cell lines and culture conditions: B16F10 murine melanoma cells were
obtained from ATCC and cultured according to ATCC directions. HCT116 human colon
carcinoma cells were a gift from Bert Vogelstein and were cultured according to ATCC
methods.

Plasmids: The plasmid pMAAC001 contains the full bacterial luciferase operon
luxCDABE driven by a T7 promoter and an ampicillin resistance cassette. The plasmid
pLuxCDE consists of the pMAAC001 backbone amplified using the forward primer
cccgggattggggaggttggtatgtaa and the reverse primer cccgggtgaatgatttgatgagccaaa (XmaI
sites underlined). This product was then XmaI digested and re-ligated to exclude the
majority of the luxA and luxB genes. pLux and pPROMOTERLux plasmids were
constructed by inserting the full bacterial luciferase operon between the KpnI and BamHI
restriction sites in the vector puc19. The pPROMOTERLux plasmid additionally had a
500 base pair promoter region (STM1787) from the Salmonella genome inserted
upstream of the luciferase operon between the SacI and KpnI restriction enzyme sites.
The 500 base pair sequence was amplified from the Salmonella genome using the
forward primer aaagagctcatttgtcgagagctgggatg and the reverse primer
aaaggtacccaggaaacggcattggtaat (SacI and KpnI sites underlined).
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Construction of a Salmonella Typhimurium reporter-trap library: Salmonella strain
SB300A1 was used to construct a bacterial library comprising approximately 7400 clones
of unique chromosomal integrations of our reporter transposon [7]. The custom Tn5based transposon was designed with the EZ-Tn5 system (Epicentre, Madison, WI) using
the pMOD4 transposon construction vector. A kanamycin-resistance cassette and
promoter from EZ-Tn5<KAN-2> was amplified using the forward primer
acgacaaagcttggacgcgatggatatgttct and the reverse primer agcttttctagaggtggaccagttggtgattt
(HindIII and XbaI restriction sites underlined) and inserted into the HindIII and XbaI
restriction sites of pMOD4. The luciferase enzyme genes luxAB from Photorhabdus
luminescens were amplified with the forward primer acagtcgaattccgccgaatgagaattgagat
and the reverse primer aagctgggtacctgttggctgctttcactcac (EcoRI and KpnI sites
underlined) and inserted between the EcoRI and KpnI sites in pMOD4 [8]. The plasmid
contained an R6Kγ origin of replication and therefore was amplified in E. coli DH5α
λpir, purified, digested with Pvu II, and the transposon fragment recovered by gel
purification. The purified transposon was combined with transposase (Epicentre). After
bench top incubation for 30 minutes, followed by 48 hours at 4°C, the transposon DNA
was electroporated into bacteria as per the vendor’s instructions. Bacteria were plated on
LB kanamycin plates to select for transformants containing the chromosomally-integrated
transposon. Each clone was expanded and stored in 60% glycerol in 96-well plates at 80°C.

Screening the library: To screen for gene activation events occurring in the context of
malignant cells, Salmonella library clones were cultured under three different conditions:
co-culture with B16F10 mouse melanoma cells, co-culture with HCT116 human colon
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carcinoma cells and culture in media alone. Each of the two tumor cell lines were seeded
into 96-well white plates at approximately 70-80% confluency in DMEM with 10% FBS.
In the plate containing media alone, each well contained 100 μl of DMEM with 10% FBS
only. Plates were incubated overnight to allow tumor cell adhesion to the 96-well white
plates. Independently, bacterial clones were grown overnight in LB broth with kanamycin
in 96-well plates and subcultured the following day 1:10 into LB broth. Five to six hours
after subculturing, 30 μl of bacterial culture were added to three replicate plates, each
corresponding to a separate culture condition. Bacteria were allowed to co-incubate with
the malignant cells or media alone for 2 hours. Subsequently, bacteria were imaged by
adding 30 μl of decanal solution, waiting 10 minutes, and imaging with an IVIS 100
imaging system (Caliper; acquisition time, 60 sec; binning, 4; filter, < 510; f stop, 1;
FOV, 23 cm) [9]. Because white plates were used to maximize signal intensity, images
were aquired utilizing a <510 filter to reduce phosphorescence from the plates. Three
control wells were included on every plate comprising: luxCDABE Salmonella
(SB300A1FL6), which contain the full luciferase operon inserted into the chromosome;
luxAB strain, which contains the luciferase enzyme genes only and therefore requires
addition of exogenous substrate to image reporter activity in the assay; and a blank well,
which contained media, but was not inoculated with bacteria, to serve as a control for
background luminescence. Imaged plates were analyzed with Living Image (Caliper) and
Igor (Wavemetric) analysis software packages as described[10]. Data were normalized by
dividing the photon flux of experimental wells by media alone wells and presented as the
log 2 of the normalized photon flux data.
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Identification of hits: Library screening data representing photon flux from each well of
a library plate were analyzed with Image J software [11]. To identify statistically
significant hits from the primary screens, we utilized a set of statistical requirements.
First, a threshold was set to identify active clones. Clones that did not produce photon
signals greater than three standard deviations above the signal in the un-inoculated, media
alone wells were not further analyzed. A quartile method of statistical analysis was then
applied to the remaining clonal data [12]. For quartile analysis, plates of clones were
grouped by assay date into sets for data analysis. For each set, we normalized data by
calculating the log 2 of the fold-change of photon flux signal between the condition of
interest (co-culture with B16F10 or HCT116 cells) and media alone. From this data, we
calculated the median (Q2), first (Q1), and third (Q3) quartile values. The boundary for
hit selection was calculated as Q3 + c(ICQ), where ICQ=Q3-Q1 and c = 1.7239,
corresponding to a high stringency targeted error rate of α = 0.0027 [12].
Verification of primary screen hits: To verify hits identified by the primary screen, clones
were tested again in a similar manner, in quadruplicate. The assay followed the same
steps as those in the primary screen, except each clone was tested in 4 wells under each of
three conditions across a 12-well row in a black 96-well plate. Imaging was done with an
IVIS 100 imaging system (acquisition time, 60 sec; binning, 4; filter, open; f stop, 1;
FOV, 23 cm).

Identification of transposon insertion site: To map sites of transposon integration in the
chromosome of clones of interest, an inverse touchdown PCR strategy was used [13].
Genomic DNA was isolated from bacteria using DNAzol (Molecular Research Center,
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Cincinatti, Ohio). PCR was performed using bacterial chromosomal DNA, 20 pmols of a
primer specific to the 5’ end of the transposon (atggctcataacaccccttg), and 100 pmols of a
degenerate primer (cggaatccggatngayksnggntc). Reactions were initiated with a 95°C
preparation step for 5 minutes, followed by 25 cycles comprising denaturation at 95°C
for 45 seconds, annealing at various temperatures for 45 seconds and extension at 72°C
for 2 minutes. The annealing temperature started at 60°C and decreased 0.5°C per cycle
for the subsequent 24 cycles. Then PCR proceeded with 25 cycles of 95°C for 45
seconds, 50°C for 45 seconds and 72°C for 2 minutes. PCR reaction products were
fractionated on a 1% agarose gel, and the most prominent bands in each lane were
excised and gel purified (Qiagen kit). For some reactions, PCR products were purified
(Qiagen) and the resulting purified PCR product was used as a template for a second
round of PCR using a different transposon-specific primer (aacatcagagattttgagacacc)
before gel purification of products. The cycling conditions and degenerate primer used in
the second round of PCR were the same as round one.

Semi-quantitative RTPCR: Salmonella strain SB300A1 was subcultured from a
stationary phase culture 1:10 and grown for 6 hours. Bacteria were then diluted 1:20 and
added to 96-well plates containing tissue culture media alone or B16F10 melanoma cells,
seeded 24 hours previously at 100,000 cells/well. After three and a half hours of coculture, extracellular media containing bacteria were removed from the 96-well plates
and triplicates pooled. Media were centrifuged to pellet bacteria and pellets were frozen
at -80°C. After thawing, pellets were resuspended in 200 μl water with 5 mg/ml lysozyme
and incubated at room temperature for 5 minutes. Then, 700 μl of RLT buffer was added
and bacterial RNA was purified using the Qiagen RNeasy kit (Qiagen Inc, Valencia, CA).
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Samples were then treated with DNase I at room temperature for 15 minutes, after which
EDTA was added and samples were incubated for 10 minutes at 65°C to inactivate the
DNase. Samples were then ethanol precipitated and resuspended in 30 μl water. For
reverse transcriptase PCR, 1 μg of total RNA was used as a template and reverse
transcribed using Superscript II Reverse Transcriptase and 300 ng random primers as per
the manufacturer’s instructions (Invitrogen, Carlsbad, CA). Following RTPCR, samples
were treated with RNase H for 25 minutes at 37°C. To perform semi-quantitative PCR,
samples were amplified using primers specific to each gene target or to ribosomal RNA:
STM1787 (forward: tcggtagatcgcatgatgtc, reverse: ggttggtcataagcctgtcg), STM1791
(forward: acacgggaacatccagattc, reverse: cggcaaaggacaaatctcat), STM1793(forward:
ttcggcaacctgtttttagg, reverse: acgcctccttgcataatcac), adiY (forward: ccttattgaccgccaactgt,
reverse: gtggtcaagaaagcgggata), yohJ (forward: caggcatttttcttgcatca, reverse:
cgccatataacgaatcagca), rrsH (forward: cagccacactggaactgaga, reverse:
gttagccggtgcttcttctg). PCR cycling conditions were: 95°C for 5 minutes, 30 cycles (or 20
cycles for rrsH reactions) of denaturation at 95°C for 45 seconds, annealing at 50°C for
45 seconds and extension at 72°C for 1 minute. PCR products were fractionated on a 1%
agarose gel.

Construction of deletion mutants: Mutant strains deficient for the identified target genes
were constructed in Salmonella strain luxCDABE msbB- (AM3), which contains a
constitutively active, chromosomally-encoded bacterial luciferase operon as well as a
mutation in msbB to create a less immunogenic LPS structure. Mutants were constructed
using a lambda red recombinase strategy [14]. First, primers were designed to amplify the
chloramphenicol-resistance cassette in pKD3 with tails flanking the targeted locus of the
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Salmonella genome to be deleted. Primer sequences specifically targetting the genome
for each mutant were used (adi forward targetting primer:
atgaaagtattaattgttgaaagtgagtttctgcatcaggacacctgggtgtgtaggctggag-ctgcttc, adi reverse
targetting primer: atcctgtttaaccggcgcatccagcggatacgggtttttgtgaatgcggtcatatgaatatcctccttag; yohJ forward targetting primer: agtaagtcactgaatattatctggcaatatatacgcgcttgtgtaggctggagctgcttc, yohJ reverse targetting primer: ttttttcgttcccttctgcccaaccactttacgctcaccgcatatgaatatcctccttag; STM1789-1793 forward targetting
primer: atgaatgcgcaacgcgtagtggtgatggggttaggaaaccgtgtaggctggagctgcttc, STM1789-1793
reverse targetting primer: ctaataaagttcatgatcgttgcggcggagggtccccaggcatatgaatatcctccttag). PCR fragments were then electroporated into AM3 bacteria expressing
plasmid-encoded red recombinase. Following electroporation, growth on
chloramphenicol plates at 37°C selected for strains that had lost the temperature-sensitive
recombinase plasmid and inserted the chloramphenicol-resistance cassette into the
targeted genomic loci. Deletion of the genes was confirmed by PCR.

Dose-response to tumor cells: To test the dose-response of hits from the screen to tumor
cell co-culture, the assay was performed as described, except that either B16F10 or
HCT116 cells were plated at 1x105; 2 x105; or 3 x105 cells per well 24 hours before coculture with bacteria. Stationary phase bacteria were diluted 1:50 and incubated for 6
hours before identical aliquots were allowed to co-culture with the malignant cells.
Imaging was done with an IVIS 100 imaging system (acquisition time, 10 sec; binning, 8;
filter, open; f stop, 1; FOV, 20 cm). Imaged plates were analyzed with Living Image
(Caliper) and Igor (Wavemetrics) analysis software packages as described [10].
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Assaying promoter activation in different pH media: Stationary phase bacteria were
subcultured 1:100 into LB broth. Five to six hrs after subculturing, 10 μl of bacterial
culture were added to 190 μl pre-warmed HEPES-buffered media in black 96-well plates
adjusted to different pH values, and allowed to incubate for three and a half hours.
Bacteria were then imaged with an IVIS 100 imaging system (acquisition time, 60 sec;
binning, 8; filter, open; f stop, 1; FOV, 20 cm).

Mouse imaging studies: To generate tumor xenografts, 6-week old nu/nu mice (Taconic)
were injected subcutaneously in the right flank with 1 x106 B16F10 cells or 2.5 x106
HCT116 cells in 100 μl PBS. Tumors were allowed to grow for two (B16F10) or three
(HCT116) weeks before bacterial challenge. Saturated cultures of strain AM3 and
deletion mutant bacteria were subcultured 1:100 into LB and grown for 3 hours. Bacteria
were then diluted to 1 x106 bacteria/ml and 100 μl were injected via tail vein. Mice were
imaged as indicated using an IVIS 100 imaging system (acquisition time, 60 sec; binning,
8; filter, open; f stop, 1; FOV, 20 cm). Photon flux data were calculated by utilizing userdetermined regions of interest (ROIs) around bioluminescent tumors with Living Image
software.

For in vivo promoter inducibility experiments, 6-week old nu/nu mice (Taconic) were
injected subcutaneously in the right and left flanks with 1 x107 HCT116 cells in 100 μl
PBS. Tumors were allowed to grow for one week. Saturated cultures of Salmonella strain
SB300A1 containing plasmids pMAAC001, pPROMOTERLux, or pLux were
subcultured 1:100 into LB and grown for 3 hours. Twenty microliters of bacterial culture
were injected intratumorally. Mice were imaged as indicated using an IVIS 100 imaging

74

system (acquisition time, 180 or 60 sec; binning, 8; filter, open; f stop, 1; FOV, 25 cm).
Photon flux data were calculated by utilizing software-determined regions of interest
(ROIs) around bioluminescent tumors with Living Image software.

Tumor ex vivo imaging: 6-week old nu/nu mice (Taconic) were injected subcutaneously
in the right flank with 1 x105 B16F10 cells and tumors allowed to grow for two and a half
weeks. Saturated cultures of bacteria were diluted and 5 x105 bacteria were injected
intratumorally. At 24 and 48 hours following bacterial injections, mice were sacrificed,
and tumors excised and dissected into 4 sections each. The bacterial-colonized tumor
sections were incubated in HEPES/Tris-buffered media at the indicated pH values and
imaged using an IVIS 100 imaging system at the indicated times (acquisition time, 180
sec; binning, 8; filter, open; f stop, 1; FOV, 12 cm).

Statistics: Error bars represent the standard error of the linearly regressed data or the
standard error of the mean where noted.

3.4 Results
To conduct a large-scale, unbiased screen for genes up-regulated by contact with
malignant cells, we used a Tn5-based transposon as the backbone of a LuxAB reporter
construct. We chose to use the bacterial luciferase enzyme genes (luxAB) only, in contrast
to the full bacterial luciferase operon (luxCDABE), because the size of the transposon
containing the full operon prohibited efficient chromosomal integration, while using only
the luxAB genes allowed for efficient genomic insertion of the transposon. The
transposon was designed to restrict reporter gene expression to only those chromosomal
integration sites downstream of an active promoter. A kanamycin resistance cassette with
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a constitutive promoter was also included to select for integration into the chromosome
(Figure 3-1a). After construction, the purified transposon was electroporated into
Salmonella Typhimurium strain SB300A1 for random chromosomal integration,
producing a 7,400 clone bacterial library[7].

Initially, the entire Salmonella library was subjected to a primary screen in the context of
three conditions: tissue culture media alone, B16F10 melanoma cells and HCT116 colon
carcinoma cells, both of the latter in monolayer co-culture with the Salmonella reporter
library. The eukaryotic tumor cells were grown in 96-well plate format overnight and
then bacterial clones added to wells corresponding to each of the two co-culture
conditions and media alone. After a two-hour incubation, bioluminescence imaging of
plates enabled identification of clones specifically up-regulating genes in the context of
exposure to melanoma and/or colon carcinoma cells (Figure 3-1a). Results of the screen
from co-culture with melanoma and colon carcinoma cells are shown in Figures 3-1b
and 3-1c, respectively. In each case, data are shown as a rank-ordered S-plot of the log 2
of the normalized signal for each clone of the library, where normalized signal was the
ratio of the signal in the condition of interest to the signal in media alone. The majority of
data points clustered around zero, indicating that most mutants interrogated in the assay
did not show tumor-specific gene regulation. However, quartile analysis with a boundary
for hit selection corresponding to a high stringency targeted error rate (α = 0.0027)
identified five candidate mutants wherein the transposon reporter was specifically upregulated during co-culture with malignant cells.
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Following the primary screen, we utilized inverse touchdown PCR to map the specific
location of each transposon in the Salmonella genome [13]. Table 3-1 documents the site
of chromosomal integration for the transposon and candidate gene up-regulated in each
isolate. All genes were novel in that they have not been previously reported to be
involved in Salmonella-host interactions, nor involved in Salmonella colonization of
neoplasia. Interestingly, the genomic insertion sites of the transposon in three of the
clones inserted in a cluster in the chromosomal sequence. Mapped to three different, but
closely linked genes (STM1787, STM1791 and STM1793, respectively), two are known
hydrogenases, and all three genes are likely co-regulated and involved in the same
Salmonella function. Although three integrations in the same putative operon may seem
to indicate a transposon insertion bias, this is not likely. Because the transposon insertion
library contained more than 7400 individual mutants, the average distance between two
different transposon integration sites was therefore approximately 650 base pairs
throughout the entire Salmonella genome. In the case of the three transposon insertions
discussed above, integration sites were located 2843 base pairs (STM1787 and STM1791)
and 2185 base pairs (STM1791 and STM1793) apart, indicating random integration by the
Tn5-based system could easily have produced this result. Sequencing showed that in one
high stringency hit, the transposon had inserted into adiY, a Salmonella gene known to be
involved in an acid tolerance response [15]. The transposon in the fifth clone was
identified to have landed in yohJ, a putative membrane protein [16].

To validate cancer cell co-culture-specific gene activation events identified in the primary
screen, we first repeated the co-culture assay in quadruplicate in at least three
independent experiments for each clone. Figure 3-2a shows the data from one
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representative experiment for clones verified by this assay. Again, all five clones showed
statistically significant enhancement of bioluminescence in the presence of tumor cells,
with a trend toward greater gene up-regulation when co-cultured with B16F10 melanoma
cells. Then, to further characterize tumor cell-induced response of Salmonella, we
utilized the tumor cells in a dose-response assay (Figures 3-2b, c). Additionally, to verify
that the reporter activation seen in the Salmonella reporter-trap clones was not an effect
of differing substrate permeability due to mutations in bacterial genes, the bacteria used
in this assay contained the original chromosomal luxAB insertion as well as a plasmid
constitutively expressing luxCDE, the biosynthetic genes for the long-chain aldehydes
that act as the optical substrates of the bacterial luciferase operon. Therefore, for this
assay, it was not necessary to add decanal to the media. Identical innoculations of
bacteria showed greater up-regulation of the reporter when exposed to greater numbers of
tumor cells in co-culture conditions, indicating that the stimuli from tumor cells
instigated a graded response from the bacteria. Because expression of the lux operon
genes fully complemented the use of exogenous decanal in the system, the data
confirmed that the effect was not an artifact of exogenous decanal permeability in the
primary screen.

Finally, to verify that the reporters in fact reflected mRNA transcriptional regulation in
wild-type Salmonella during co-culture with tumor cells, we utilized semi-quantitative
PCR. Following a three-hour co-culture of wild-type (SB3001A1) bacteria with B16F10
cells or in tissue culture media alone, isolated RNA was reverse transcribed to cDNA.
Semi-quantitative PCR of the cDNA showed co-culture with B16F10 melanoma cells
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enhanced the intensity of target gene transcripts, but not of the control ribosomal RNA
transcripts (rrsH) (Figure 3-2d).

Notably, of the genes identified in this screen, at least one, adiY, has previously been
reported to be up-regulated in acidic pH conditions [15]. One characteristic of tumor
microenvironments in vivo is an abnormally acidic pH [17]. For these reasons, the
Salmonella transposon insertion mutants were further investigated for reporter signal
activation in acidic conditions. Figure 3-3 shows that reporter signals increased in acidic
pH media compared to neutral media. Each of the clones up-regulated the reporter gene
at pH 6.0 compared to the physiological pH of normal body tissue (pH 7.5), suggesting
that the stimulus Salmonella responded to in the context of neoplastic cells was
microenvironment acidification.

To determine whether the activated genes were required for localization to tumors or
required for colonization and growth within tumors in vivo, Salmonella strains mutant for
genes identified in the screen were constructed. Selected genes were deleted using a
lambda red recombinase insertional deletion strategy, which inserted a chloramphenicol
resistance cassette into the targeted genes. The deletion mutants were created from a
parental Salmonella strain (luxCDABE msbB-) containing a chromosomally-integrated
and constitutively-expressed bacterial luciferase operon for imaging bacterial
localtization in vivo in real time. The stain also contained a msbB gene deletion, which
causes a less immunogenic LPS structure and minimizes septic shock effects when the
strain is administered intravenously [3]. Based on the analysis that the identified
STM1787, STM1791 and STM1793 genes were contained in a single operon, we targeted
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a large region of this operon for deletion in a single mutant strain, 1789-1793-. The gene
adiY also appeared to be a part of a larger operon of co-regulated genes and was therefore
targeted along with the adjacent genes adi and yjdE. The gene yohJ was targeted
individually. In a B16F10 melanoma tumor xenograft model, all bacterial strains were
injected via mouse tail vein and deletion mutants compared to the parental strain for
localization to and persistence within the tumor using bioluminescence imaging (Figure
3-4). All mutant strains and the parent strain were capable of tumor localization and
persistence, indicating that the identified genes were not essential for bacterial
colonization of the tumor. The experiment was also performed in an HCT116 colon
carcinoma xenograft model with similar results. Table 3-2 details the numbers of mice
with colonized tumors on or before day 10 in each experiment.

We next sought to demonstrate the specificity of selected promoter activation in the
tumor microenvironment in vivo. Here, we used the constitutively bioluminescent
Salmonella strain Tn:27.8+pluxCDE or the conditionally bioluminescent strain
Tn:1787+pluxCDE, each of which constitutively express plasmid-encoded luxCDE, but
the latter strain will only bioluminesce upon activation of the chromosomally-encoded
luxAB reporter. In a B16F10 melanoma tumor xenograft model, bacteria were injected via
mouse tail vein or intratumorally and allowed two days to localize and adapt to tumors in
vivo. Tumors were then excised, incubated in solutions of various pH values and imaged
periodically for six hours. Initially, all tumors showed bioluminescent bacteria ex vivo.
Over time, constitutive Tn:27.8 Salmonella showed an increase in signal consistent with
bacterial growth in the tumor explants. This behavior was also observed in the Tn:1787
Salmonella-infected tumor suspension in low pH media. By contrast, when the Tn:1787
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Salmonella-infected tumor was maintained in basic media conditions throughout, the
signal initially increased, but then plateaued around 4 hours and decreased in comparison
to the constitutively bioluminescent Tn:27.8 strain (Figure 3-5). This finding indicated
that bacterial gene expression was initially engaged by the low pH conditions of the in
vivo tumor microenvironment, but after exposure to a higher pH environment ex vivo, the
promoter driving the reporter was repressed and signal declined. Further, this ex vivo
effect was reversible. When the medium on the Tn:1787 Salmonella-infected tumor
suspension was changed from pH 6.0 to pH 7.5, the bioluminescent signal decreased.
Conversely, when the media was changed from pH 7.5 to pH 6.0, the signal increased
(Figure 3-5b). These effects were not seen with the constitutive Tn:27.8 Salmonellainfected tumor explants, and provided further evidence in support of the specificity of the
trapped Salmonella promoter in the Tn:1787 transposon mutant for the tumor
microenvironment.

Because the identified Salmonella genes were dispensable for tumor localization, but
their respective promoters were activated in the tumor microenvironment, these strains
provided a unique opportunity to design tumor-targeting bacterial vectors subject to
various levels of controlled specificity. Thus, we sought to determine if the acidic pH of
the tumor microenvironment could be exploited to specifically activate a target transgene
during tumor localization. As proof of principle, we constructed Salmonella reporter
strains expressing plasmids encoding the bacterial luciferase operon driven by either
constitutive promoters or an inducible promoter to demonstrate tumor-mediated
transgene activation in vivo. The plasmids pMAAC001 and pLux both encoded
constitutively-expressed luciferase operons, while the pPROMOTERLux plasmid was
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engineered to contain the luciferase operon driven by the Salmonella candidate promoter
(STM1787) comprising 500 base pairs upstream of the putative transcription start site of
tumor-activated genes STM1787, STM1793 and STM1791 (which we will now refer to as
the STM1787 promoter). Bacteria expressing these plasmids were identically injected into
mice bearing HCT116 tumor xenografts on each flank (Figure 3-6). We chose to utilize
intratumoral injection to directly compare reporter gene activation from two different
bacterial strains, one inducible and the other constitutive, over time in the same mouse.
Although reporter signals from pPROMOTERLux-expressing bacteria were low
immediately after injection into the tumor, the bacteria quickly induced a 90-fold
enhanced expression of the reporter after an 8 hr exposure to the tumor
microenvironment (Figure 3-6a). Concurrently, bacteria constitutively expressing pLuxor pMAAC001-luciferase showed <20-fold or no reporter activation, respectively, after
exposure to the tumor microenvironment (Figures 3-6a and 3-6b). These data directly
demonstrated tumor-specific induction of a transgene from the Salmonella STM1787
promoter in an in vivo system. Therefore, the STM1787 promoter could be used as a
platform to design tumor-targeting Salmonella strains capable of specifically delivering a
therapeutic gene or toxin to the site of a tumor in vivo.

3.5 Discussion
Salmonella Typhimurium bacteria are typically classified as human gastrointestinal
pathogens and a common cause of modern food-borne illness. However, another noted
characteristic of Salmonella is the bacterium’s coincident colonization of tumor tissue. In
fact, in the 1800’s, some physicians began to intentionally use bacteria as tumor
therapeutics. Yet, due to significant toxicity and lack of consistent, reliable results, these
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practices were abandoned. However, more recent studies using longitudinal imaging
demonstrate Salmonella colonization of tumors in real time and have sparked a renewed
interest in this concept using Salmonella [1, 18] as well as various other tumor-localizing
microbes as an option for cancer treatment [19-25].

A number of these studies capitalize on utilizing bacteria as treatments per se or as drug
delivery vehicles, by exploiting their potentially low toxicity and high tractability [23,
26-30]. Various attenuated Salmonella strains have been developed for use in tumortargeting studies, including specific amino acid auxotrophs and LPS mutants [3, 31].
However, the greatly reduced toxicity of Salmonella LPS mutants (msbB-) observed in
swine models has not been observed in mouse models [32, 33]. In more than one
instance, attenuated Salmonella have even been used in a clinical trial to treat cancer in
humans [33-35]. However, trials so far show relatively low rates of tumor colonization in
human hosts, which may be due to excessive attenuation of bacteria [32, 36].
Additionally, one study indicates that induction of TNFα by bacteria is necessary for
optimal colonization of tumors [37]. Nonetheless, few studies have investigated the
phenotypic and gene expression patterns of these tumor-targeting bacteria following
exposure to tumor cells.

Tumor-targeting bacteria present a challenge: how to produce a bacterial strain
sufficiently attenuated to limit side effects, but not so attenuated that tumor colonization
is unlikely. One approach to this problem is to increase the tumor specificity of the
treatment strategy. By using bacterial strains containing therapeutic gene products for
which expression is specifically activated in the tumor microenvironment, it may be
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possible to reduce the dose of potentially toxic bacteria. However, the ideal location for
this transgene in the Salmonella genome must demonstrate two critical properties. First,
the location must be highly up-regulated in the tumor microenvironment. Second, the
insertion of a gene at this site must not disrupt the ability of the Salmonella to target and
colonize tumor tissues. Candidate genes that meet the above criteria may serve as ideal
target sites for inserting therapeutic transgenes.

In this study, we utilized an engineered transposon to interrogate the Salmonella genome
for genes activated during exposure to cancer cells. Toward this objective, we generated a
library of greater than 7,400 independent transposon insertions, which, assuming random
integration, would predict genomic coverage of approximately 1.5X. From this library,
we identified five Salmonella genes specifically up-regulated during co-culture with
cancer cells, STM1787, STM1791, STM1793, adiY and yohJ. Following identification of
these tumor cell-activated genes, verification in secondary assays and confirmation in
wild-type Salmonella, we determined that the common stimulus for up-regulation of
target gene expression was acidic pH. In another study aimed at identifying Salmonella
promoters involved in tumor colonization in vivo, Salmonella genomic DNA was
digested and ligated randomly upstream of a GFP reporter. In this study, the major
stimulus identified in reporter activation was hypoxia, but no pH-regulated promoters
were identified [38]. While pH and hypoxia are physiologically linked, the five genes
identified herein show no overlap with the promoters identified by Arrach et. al. [38].
The lack of concordance may reflect the different strategies for gene identification or the
inherent enhanced sensitivity of bioluminescence readouts (due to the lack of background
signals) compared with fluorescence. Nonetheless, hydrogenase genes are noted in some
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cases to be up-regulated in low oxygen conditions, indicating that hypoxia may serve as a
further stimulus for the pH-induced promoters identified in the present study [39].
However, in pilot studies using an incubation pouch system used for growing anaerobic
bacteria, we did not observe any significant changes in transposon reporter activity (KF,
unpublished data). While these data don't necessarily rule out entirely oxygenindependence, pH appeared to be the dominant signal inducing responses in the
promoters identified by our bioluminescent transposon reporter-trap screen.

In view of the usual pathophysiology of Salmonella, it is not surprising that Salmonella
strains have gained the ability to precisely regulate genes in response to different pH
environments. Salmonella encounter low pH conditions regularly during human
infection, for example, during transit through the stomach, and later during intracellular
trafficking through the phagosome [40, 41]. Interestingly, the acidic pH of the tumor
environment in vivo has long been noted as an important microenvironmental condition
when designing effective tumor treatment techniques [17, 42]. Additionally, the low pH
environment of the tumor inhibits host defense. Cytotoxic immune cell activity and
cytokine secretion has been shown to be impaired by a low extracellular pH [43, 44]. In
contrast, with a bacterial-driven tumor therapeutic, low pH may become an exploitable
advantage, by adding another level of selectivity to bacterial gene activation. In this case,
a bacterial-based system may succeed, while both conventional therapeutics and host
defenses fail.

When using bacteria as a vector for drug delivery studies, tumor-specific expression is a
major concern. The genes identified herein are highly expressed in an acidic pH tumor
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environment, but are not required for bacterial tumor targeting. Therefore, the promoters
regulating these genes may be ideal candidates for utilization in therapeutic gene, prodrug or toxin delivery studies. We have identified the STM1787 promoter as an ideal
bacterial sequence capable of driving tumor-specific expression of a transgene, and
demonstrated this in vivo using bioluminescent imaging. By adapting the STM1787
promoter in Salmonella to drive expression of an appropriate therapeutic transgene, the
resulting bacterial vector would provide two independent mechanisms for specifically
targeting tumors. First, Salmonella specifically localize to and accumulate in tumors in
vivo. Second, the STM1787 promoter is preferentially activated in the acidic tumor
microenvironment. The combined effect of these two levels of specificity provides a
potential option to design more successful bacterial therapeutics in the future.
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3.6 Tables

Table 3-1. Transposon chromosomal insertion locations in Salmonella reporter mutants.
Strain Name

Transposon Insertion
Location

Function
(Putative) [16]

STM1787

Base pairs
Downstream of
Start Codon
1,189

Tn:1787
Tn:1791

STM1791

505

Hydrogenase

Tn:1793

STM1793

661

Tn:adiY

adiY

439

Tn:yohJ

yohJ

205

Cytochrome
oxidase
araC-like
transcriptional
activator;
argininedependent acid
tolerance
Hypothetical
membrane protein
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Hydrogenase

Table 3-2. Tumor localization of constitutively bioluminescent Salmonella mutants.
Mutant

Number of Mice with
Bioluminescent, Colonized
Tumors/Total Mice Injected
(HCT116 Colon Carcinoma)

luxCDABE
STM1789-1793
adi
yohJ

2/3
2/3
1/2
3/3
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Number of Mice with
Bioluminescent, Colonized
Tumors/Total Mice
Injected
(B16F10 Melanoma)
3/4
2/5
4/5
3/5

Totals

5/7
4/8
5/7
6/8

3.7 Figures
Figure 3-1
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Figure 3-1. Design and utilization of a high throughput screen to identify tumor cellinduced gene activation events in Salmonella. (a) A schematic of the promoter trap
system using Tn5-based luxAB chromosomal integration. Expression of the promoterless
luxAB reporter vector, and resulting Salmonella bioluminescence, is dependent on
“trapping” an active promoter upstream of the chromosomal integration site. The
transposon was randomly integrated into SB300A1, and kanamycin-resistant colonies
were selected and arrayed into 96-well plates for library screening. Representative
primary screening plates in triplicate show responses of Salmonella library strains to
three separate co-culture conditions: media alone (top), B16F10 melanoma cells (bottom
left), HCT116 colon carcinoma cells (bottom right). Hit 47.74, showing selective
activation in co-culture with cancer cells, is indicated by the black open arrowhead, while
the signals in the upper and central wells represent non-selective activation of clones. In
each plate, wells H10, H11, and H12 (red box) contain media and bacteria constitutively
expressing luxCDABE, bacteria constitutively expressing luxAB, and no bacteria,
respectively, as controls. Primary library screening data from Salmonella promoter trap
clones co-cultured with B16F10 melanoma cells (b) or HCT116 colon carcinoma cells
(c). Data are reported as the log 2 of the normalized signal for each library clone, where
normalized signal was the ratio of the signal in the condition of interest to the signal in
media alone.
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Figure 3-2
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Figure 3-2. Verification of Salmonella gene activation events in the context of tumor
cell co-culture. (a) Salmonella reporter clones displaying gene activation signals during
co-culture with tumor cell lines (black bars, B16F10 melanoma cells; open bars, HCT116
colon carcinoma cells). Salmonella strains luxAB and Tn:27.8 contain chromosomal
luxAB genes under constitutive promoter control; luxCDABE Salmonella contain the full
luciferase operon inserted into the chromosome; pMAAC001 constitutively expresses
plasmid-encoded luxCDABE. (b, c) Salmonella reporter clones display dose-responsive
gene activation in co-culture with B16F10 and HCT116 cells. Bacteria were co-cultured
with 1x105, 2x105, or 3x105 B16F10 or HCT116 cells/well. Data were normalized as the
ratio of the signal in the condition of interest to signal in media alone. Error bars
correspond to SEM. All p value calculations are between luxCDABE and the group
indicated by the symbol: (*), p ≤ 1x10-7; (x), p ≤ 0.06. (d) Semi-quantitative reverse
transcriptase PCR with wild-type SB300A1 bacteria verifies that genes identified by the
reporter transposon screen in Salmonella are activated during co-culture with B16F10
melanoma cells. rrsH = ribosomal RNA.
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Figure 3-3

Figure 3-3. Acidic pH stimulates targeted Salmonella gene activation. Bacteria were
cultured in media of different pH values and reporter activation by Salmonella library
clones in low pH media (pH 6) were compared to reporter activation in normal pH (7.5).
Genes identified in the tumor cell co-culture screen were activated in the context of acidic
pH compared to pH 7.5. pMAAC001 and luxCDABE constitutively express plasmidencoded and chromosomally-encoded luxCDABE, respectively. Data were normalized as
the ratio of the signal in media pH 6.0 to signal in media pH 7.5. Error bars correspond to
standard error. The data show one representative experiment with 4 replicates per
condition tested. All p-value calculations are between luxCDABE and the group indicated
by the asterisk (*), p ≤ 2x10-14.
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Figure 3-4

Figure 3-4. Activated genes are not essential for Salmonella tumor localization. Mice
bearing B16F10 melanoma flank tumor xenografts were injected intravenously with
constitutively bioluminescent mutant Salmonella. (a) Representative mice on day 10 post
Salmonella injection. (b) Bioluminescent photon flux of the four mice depicted in (a) as a
function of time following injection of bacteria.
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Figure 3-5

Figure 3-5. The Tn:1787 trapped promoter is specifically and reversibly activated
by the pH of the tumor microenvironment. Mice bearing B16F10 melanoma flank
tumor xenografts were injected intratumorally with tumor-activated (Tn:1787+pluxCDE)
or constitutively bioluminescent (Tn:27.8+pluxCDE) Salmonella. (a) The excised tumors
were imaged hourly and data are presented as the normalized signal at each time point.
The normalized signal represents the ratio of the mean of the fold-initial signal of two
Tn:1787+pluxCDE-colonized tumors to the mean of the fold-initial signal of two
constitutive Tn:27.8+pluxCDE-colonized tumors. The data presented are from a
representative experiment; the experiment was performed independently two times, each
with two mice per bacterial treatment group. (b) Representative ex vivo tumor imaging
shows reversibility of the bioluminescent signal in the tumor-activated Salmonella.
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Images on the left show Salmonella-infected tumor explants after 6 hours of incubation at
the indicated pH (pH 6.0, top; pH 7.5, bottom). Two hours later (8 hours total), media
was removed and replaced with media of the indicated pH (pH 7.5, top; pH 6.0, bottom).
Images on the right show Salmonella-infected tumor explants 4 hours after the pH of the
media was changed.
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Figure 3-6

Figure 3-6. The STM1787 promoter in Salmonella is rapidly activated in vivo by the
tumor microenvironment. (a) A representative mouse with two HCT116 colon
carcinoma flank tumor xenografts. The left tumor (black arrow) was injected with
STM1787 pPROMOTERLux-expressing Salmonella, while the right tumor (red arrow)
was injected with constitutive pMAAC001-expressing Salmonella, and the mouse imaged
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at the indicated times post-injection. (b) The mean photon flux for each set of
Salmonella-injected tumors, normalized to the initial signal in each tumor, plotted as a
function of time. Error bars represent SEM; pPROMOTERLux (n=6); pLux (n=3);
pMAAC001 (n=3).
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CHAPTER 4
A High-Throughput siRNA Screen Identifies Nucleoside
Diphosphate Kinase (NME3) as a Novel Host Regulator
of NF-κB Signaling in Response to Salmonella-Induced
Activation of TLR-5
4.1 Abstract
Salmonella is a well-known activator of the innate immune system by engaging NF-κB
signaling. In this work, we now demonstrate Salmonella-induced IKK activation and the
resulting NF-κB transcriptional activation in real time. We show that in HCT116 colon
carcinoma cells, flagellin is the predominant ligand accounting for Salmonella induction
of NF-κB. Then, an siRNA library targeting 691 known and predicted human kinases
was screened in HCT116 colon carcinoma reporter cells expressing a κB 5 IκBα-FLuc
reporter to identify novel host kinase modulators of flagellin-induced NF-κB activation.
This screen uncovered nucleoside diphosphate kinase (NME3) as a previously
unrecognized, positive regulator of Salmonella-induced NF-κB signaling.

4.2 Introduction
The bacterial pathogen Salmonella Typhimurium commonly causes gastrointestinal
illness in human hosts and is transmitted by ingestion of contaminated food and water. In
the host, the bacteria invade intestinal epithelial cells, causing tissue destruction,
inflammation and diarrhea. In some instances, a severe Salmonella infection can
damage the intestinal barrier so severely that the bacteria penetrate this barrier, invade
infiltrating phagocytes and progress to a systemic infection. In order to protect itself
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against bacterial infections, the host employs a robust set of first line defenses
collectively referred to as innate immunity. One important component of host innate
immunity consists of a series of pattern recognition receptors activated by common
foreign antigens, or PAMPs (pathogen associated molecular patterns). These receptors
include Toll-like receptors (TLRs) and NOD receptors, both of which are involved in
activation of inflammatory signaling.
Over the years, multiple TLRs have been identified, several of which are activated by
Salmonella. Salmonella is capable of activating TLR2, TLR4 and TLR5 through its
peptidoglycan (PG), lipopolysaccharide (LPS) and flagellin [1]. Once bound, these
receptors induce downstream signaling in host cells resulting in activation of proinflammatory pathways, one of which is NF-κB [1]. To initiate NF-κB signaling, TLRs
induce a downstream kinase cascade that results in activation of IKK, which
phosphorylates IκBα, the negative regulator of NF-κB[1]. Ubiquitination and
degradation of IκBα frees NF-κB to translocate into the nucleus and activate downstream
transcriptional programming to promote inflammation and immune responses [1].
Salmonella engagement of TLRs and activation of NF-κB serves primarily to alert the
host of invading pathogens. However, Salmonella recognition by TLRs may result in at
least two potentially deleterious downstream effects in host cells. First, it has been
shown that Salmonella capitalizes on host TLR activation to induce bacterial virulence
factor expression, indicating that the bacteria have evolved mechanisms to increase their
virulence in response to detection by the host cell [2]. Second, NF-κB activation leads to
pro-proliferative signaling in host cells, and over-activation of these pro-proliferative
signals has been linked to cancer [3]. Indeed, chronic bacterial infections, including
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those by Salmonella species, have been linked to carcinogenesis [3, 4]. Therefore, a
better understanding of the signaling pathways specifically induced during Salmonella
colonization is necessary to fully understand how to best combat infection.
In this work, we have identified flagellin as the predominant immunostimulatory PAMP
of Salmonella-induced activation of NF-κB signaling in HCT116 colon carcinoma cells.
We then utilized a high-throughput approach to search for previously unidentified host
modulators of Salmonella-induced NF-κB signaling. We identified NME3, a eukaryotic
kinase, as an important regulator of NF-κB signaling activity.

4.3 Methods
Cell lines and culture conditions: HCT116 cells were a gift of Bert Vogelstein and
cultured according to ATCC directions. All stably transfected HCT116 cells were
cultured in 0.5 µg/ml puromycin.
Salmonella strains: Salmonella Typhimurium strain SL1344 was used for all
experiments, except where noted. All mutants (fliC-, fljB- and fliC-fljB-) were
constructed using a lambda red recombinase strategy [5]. First, primers were designed to
amplify the kanamycin- or chloramphenicol-resistance cassette in pKD4 or pKD3 with
tails flanking the targeted locus of the Salmonella genome to be deleted. PCR fragments
were then electroporated into SL1344 bacteria expressing plasmid-encoded red
recombinase. Following electroporation, growth on kanamycin or chloramphenicol plates
at 37°C selected for strains that had lost the temperature-sensitive recombinase plasmid
and inserted the chloramphenicol-resistance cassette into the targeted genomic loci. The
double mutant strain was created in a step wise manner, by individually deleting each
gene. Deletion of the genes was confirmed by PCR.
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Creation of a κB5IκBαFLuc-expressing HCT116 stable cell line: HCT116 cells at 95%
confluency were co-transfected with 10 µg of pκB5IκBαFLuc and 3 µg of pIRES-puro
plasmid DNA using Fugene 6 in 10 cm dishes. After 24 hours, the media was replaced
with fresh cell media. Twenty-four hours later, the cells were split at multiple dilutions
into media containing 0.5µg/ml puromycin to select for stable transformants. After two
weeks, isolated cell colonies were imaged to check for reporter gene expression and
bioluminescent colonies were harvested and expanded. The cells were continuously
cultured in the presence of 0.5µg/ml puromycin to maintain expression of the reporter
plasmid.
Transient transfections of HCT116 cells: HCT116 cells were transiently transfected
where noted. Cells were plated in 24-well (50,000-60,000 cells/well) or 96-well (10,000
cells/well) plates and transfected with Fugene 6 (Roche) and 200 ng of plasmid DNA(24well) or 50 ng of plasmid DNA (96-well) per well. In the case of NME3 over-expression
experiments, 100 ng of reporter plasmid and 200 ng of over-expression (pCMV6:NME3)
or vector control (pCMV6) plasmid were used in each well of a 24-well plate. Cells were
allowed to recover for 48 hours prior to imaging.
Dynamic imaging of NF-κB signaling: Thirty minutes prior to imaging, cell media were
aspirated and replaced with colorless DMEM supplemented with 10% heat-inactivated
FBS and 150 µg/ ml luciferin. To image, cells were stimulated as indicated and imaging
was performed in an IVIS 100 imaging system (except where noted), with images being
acquired every 5 minutes for 6 hours, unless otherwise indicated. The cells were
maintained in the imaging chamber by a heated stage (37ºC) and 5% CO 2 air flow.
Stimuli included: SL1344 Salmonella Typhimurium , or indicated mutants, confluent
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culture (final dilution 1:100 in well) or matched for OD 600 , heat-killed by boiling 10
minutes and diluted 1:10 into each well (where noted), lipopolysaccharide (1µg/ml)
(Sigma), peptidoglycan (Sigma), ie-DAP(10µg/ml) (InvivoGen), MDP (10µg/ml)
(InvivoGen), TNFα (20 ng/ml) (R & D systems), or flagellin (100 ng/ml) (InvivoGen).
Acquisition parameters are noted in the figure legends.
High-throughput screen: siRNA screening was performed in white, clear-bottomed, 96well culture plates using a Beckman-Coulter Core robotics system, including an FX
liquid handler, controlled by the Sagian graphical method development tool (SAMI
scheduling software). HCT116 cells stably expressing pκB5IκBαFLuc were seeded at
15,000 cells per well in a 96 well plate and cells were allowed to attach for 24 hours.
Forward transfection was performed with a 96 multichannel head on the FX liquid
handler, adding 0.5 µl/well of media-complexed R1 Transpass (NEB) to the aliquotted
siRNA library (Kinase siRNA set v2; Qiagen Inc.) in a 96-well reaction plate and
allowed to incubate for 15 minutes. Experimental siRNA oligos were arrayed in columns
2-11 of each plate and individual controls comprising vehicle-treated wells, a nontargeting control sequence (Qiagen Allstar Negative control), TLR5-targetting siRNA
sequences (IDT), and a firefly luciferase-targeting PGL3 siRNA (Dharmacon Research
Inc.) were placed manually in columns 1 and 12. After incubation of siRNA complexes,
100 µl was added to each well of a plate with cells (x3 plates) using the FX liquid
handler, yielding a final concentration of ~50 nM siRNA/well. Plates were maintained at
37ºC and 5% CO 2 for 48 hrs. At this time, media were aspirated and replaced with 180
µl imaging media (colorless DMEM supplemented with 10% heat inactivated FBS and
150 µg/ml d-luciferin) and the cells were allowed to equilibrate for 45 minutes. After
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equilibrating, 20 µl of stimulus (1:100 dilutions of heat-killed Salmonella cultures) or
control (LB broth) were added to each well. Bioluminescent readings were obtained on
an EnVision plate reader (PerkinElmer) immediately following the stimulus, at 45
minutes post-stimulation and at 245 minutes post-stimulation. After the final luminescent
reading, 20 µl of rezasurin dye was added to all wells, allowed to incubate for 2 hours at
37⁰C and monitored on a FLUOstar OPTIMA fluorescence reader for cell viability
(BMG Labtech; excitation, 544 nm, emission, 590 nm).
Data analysis: Initially, the signal in each well was normalized to a plate-matched
control well containing a non-targeting siRNA sequence at each time point to facilitate
experiment-wide analysis. Then, the differences in the log 2 values of the normalized data
between 0 minutes and 45 or 245 minutes were averaged across triplicate siRNA
experimental replicates. Then, screening hits were selected by quartile analysis of the
normalized kinase library data. To perform the quartile analysis, median (Q2), first (Q1)
and third (Q3) quartile values were calculated. From these values, the upper and lower
boundaries for hit selection were calculated as Q3 + 2c(Q3 –Q2) and Q1 – 2c(Q2-Q1),
respectively, for c = 1.2245 corresponding to a high-stringency targeted error rate (α =
0.02) and for c = 0.7193 corresponding to a low-stringency targeted error rate (α = 0.1)
[6].
siRNA knockdown: siRNA knockdown of NME3 was performed utilizing 4 separate
targeting sequences. Stably-transfected HCT116 cells were plated in 96-well plates at
15,000 cells/well and allowed to incubate overnight. Twenty-four hours later, cells were
transfected with R1 Transpass (NEB) and 25 nM siRNA (Qiagen) as per R1 Transpass
instructions. Cells were incubated for 72 hours prior to imaging.
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shRNA lentiviral knockdown cell line construction: Lentivirus, expressing constructs
(pLKO.1 puro), were obtained pre-synthesized from the Genome Sequencing Center at
Washington University. The targeting sequences for the 3 shNME3 constructs are as
follows:
#7 - 5’ GAGGTTGGCAAGAACCTGATT
#8 - 5’ GCCTTGTCAAGTATATGGCCT
#9 - 5’CGAGAGGAAGGGCTTCAAGTT
Additionally, a scrambled shRNA construct was utilized as a negative control. To
generate lentivirus containing hairpins, 500,000 293T cells were pre-plated in 60 mm
dishes and co-transfected the following day with 1 µg of hairpin construct, 900 ng
packaging plasmid pCMV-ΔR8.2, and 100 ng of envelope plasmid pVSVG using Fugene
6. Two days after transfection, virus containing supernatant was collected from 293T
cells and filtered through a 0.45µm filter, mixed with 5ug/ml protamine sulfate, and
added to HepG2 cells at 50% confluency in a 10cm2 dish. Media was replenished 12 hrs
post-transduction, and cells were subsequently maintained in media supplemented with
500 ng/ml puromycin hydrochloride to retain expression of the hairpins. Following
transduction, shNME3 or shSCRAMBLED cells were plated in parallel for mRNA
knockdown confirmation and transient transfection and subsequent imaging
measurements with the κB 5 →IκBα-FLuc reporter or the κB 5 →FLuc reporter as
previously described.
Semi-quantitative RTPCR: HCT116 cells transduced with shNME3 or shSCRAMBLED
hairpins were lysed and total RNA was purified using the Qiagen RNeasy kit (Qiagen
Inc, Valencia, CA). Samples were then treated with DNase I at room temperature for 15
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minutes, after which EDTA was added and samples were incubated for 10 minutes at
65°C to inactivate the DNase. Samples were then ethanol precipitated and resuspended in
water. For reverse transcriptase PCR, 1 μg of total RNA was used as a template and
reverse transcribed using Superscript II Reverse Transcriptase and 300 ng random
primers as per the manufacturer’s instructions (Invitrogen, Carlsbad, CA). To perform
semi-quantitative PCR, samples were amplified using 2 μL or RT reaction and primers
specific to NME3 or GAPDH. PCR cycling conditions were: 95°C for 5 minutes, 35
cycles (or 25 cycles for GAPDH reactions) of denaturation at 95°C for 45 seconds,
annealing at 55°C for 45 seconds and extension at 72°C for 1 minute. PCR products were
fractionated on a 1% agarose gel.

4.4 Results
To study IKK-induced activation of NF- κB by Salmonella in real time in living cells, we
utilized a bioluminescent κB 5 →IκBα-FLuc fusion reporter. This reporter consists of the
negative inhibitor of NF-κB, IκBα, directly fused to firefly luciferase. When the
upstream kinase, IKK, is activated, it phosphorylates IκBα proteins in the host cell,
targeting them for ubiquitination and proteasomal degradation. In this case the reporter
fusion protein serves as a direct readout of IKK activity [7]. As activated IKK
phosphorylates IκBα, the reporter fusion is phosphorylated, ubiquitinated, and targeted
for degradation as well. This results in a reduction in bioluminescent reporter activity
that can be followed in real time [7]. Liberation of NF-κB from its inhibitor frees it to
translocate to the nucleus and activate transcription at NF-κB response elements. The
reporter fusion is linked on its 5’ end to five of these response elements in tandem,
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allowing it to report on NF-κB nuclear transactivation ability as well by measuring an
increase in bioluminescent signal [7]. Stimulation of HCT116 cells with heat-killed
Salmonella robustly activates degradation and resynthesis of the reporter fusion, which
can be imaged periodically to visualize the changes in reporter photon output following
stimulation (Figure 4-1a). Heat-killed bacteria were preferred as a stimulus over live
bacteria. When performing the assay with live Salmonella, replication by the bacteria
quickly changed the media conditions, ultimately leading to complete attenuation of the
luciferase signal (data not shown). The data obtained from imaging HCT116 cells
stimulated with heat-killed Salmonella can also be represented graphically to demonstrate
the dynamics of the reporter in the system (Figure 4-1b). After stimulation with bacteria,
the reporter signal initially decreased to 60% of its steady state level prior to activation.
Following this decrease, which corresponds to IκBα degradation, the Salmonella-induced
reporter activity rebounds to greater than three times the original bioluminescence levels,
corresponding to transcriptional activation of the IκBα-FLuc fusion protein. In
comparison, TNFα, a common stimulus of NF-κB signaling, elicits more degradation and
less transcriptional activation of the reporter. Additionally, the dynamics of the HCT116
cellular response to TNFα differ from those observed when HCT116 cells respond to
Salmonella. The peaks of reporter degradation and resynthesis both occur earlier
following stimulation with TNFα, indicating differences in the signal transduction
following the different stimuli.
To understand how the HCT116 colon cancer cells are recognizing Salmonella and
activating pro-inflammatory signaling, we set out to isolate the specific NF-κB activating moiety of the bacteria. To accomplish this, we tested the NF-κB stimulatory
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activity of individual known immunostimulatory components of bacteria. When tested in
HCT116 cells stably expressing the κB 5 →IκBα-FLuc reporter, purified peptidoglycan,
NOD ligands (ieDAP and MDP), and bacterial LPS were all incapable of inducing
significant bioluminescent reporter activity changes (Figure 4-2a-c).

Because bacterial

flagellin is noted for its immunostimulatory activity, we chose to investigate its
contribution to NF-κB activation by Salmonella. To better determine the contribution of
the two Salmonella flagellin proteins to NF-κB stimulation, we constructed Salmonella
strains mutated singly or in both flagellin genes fliC and fljB. Both single mutants were
still able to activate NF-κB signaling, albeit to a lesser extent than that of wild type
bacteria, but the Salmonella double mutant was incapable of activating NF-κB signaling
in HCT116 cells. This indicated that flagellin was the predominant ligand inducing NFκB signaling in HCT116 colon carcinoma cells (Figure 4-3). Further, purified
Salmonella flagellin also activates NF-κB signaling in this system although to a lesser
extent than heat-killed Salmonella (data not shown). This may reflect a difference in the
amount of flagellin produced by bacteria compared to the concentration of purified
flagellin used, a difference in solubility between bacterially-produced and purified
recombinant flagellin, or a difference in the relative amounts of monomeric versus
polymerized flagellin in the two preparations. Alternatively, perhaps heat-killed bacteria
provide an additional co-activating ligand, in which case flagellin is necessary, but not
sufficient to fully induce NF-κB signaling.
With the knowledge that HCT116 cells are robustly activating proinflammatory signaling
in response to Salmonella flagellin, we set out to identify novel host kinases involved in
immunodetection of Salmonella. We utilized an siRNA screen to all known and predicted
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human kinases to test the involvement of each in Salmonella-induced activation of NFκB. The screen consisted of utilizing HCT116 cells colon carcinoma cells stably
expressing the κB 5 →IκBα-FLuc construct. Cells were plated and transfected with siRNA
targeting 691 host kinases arrayed in the 10 center columns of 96-well plates with each
well containing two sequences targeting a single host kinase. Forty-eight hours following
siRNA transfection, cells were stimulated with heat-killed Salmonella and the reporter
signal was measured immediately, at 45 minutes and at 245 minutes following the onset
of Salmonella exposure (Figure 4-4). Normalized bioluminescence signal data at 45 and
245 minutes were plotted individually (Figure 4-5), or as x-y coordinates being the
normalized signals at 45 and 245 minutes respectively (Figure 4-6).
High-throughput screening hits were determined using a quartile-based analysis. Figure
4-5 displays the quartile-identified values for low- and high-stringency hit selection.
Wells in which kinases that positively affect NF-κB signaling targeted by siRNA will
demonstrate reduced responsiveness to Salmonella. In contrast, wells containing siRNA
targeting a negative regulator of NF-κB signaling will show enhanced reporter response.
Statistically significant hits and their predicted regulatory activity on NF-κB signaling are
listed in Table 4-1. Figure 4-6 demonstrates the four possible effects kinases in the
screen may have had on reporter activity. Kinase knockdowns reducing the photon flux
signal at 45 minutes, i.e., increasing IκBα degradation, indicate a negative regulator of
NF-κB signaling has been targeted. Meanwhile, kinase knockdowns with relatively
greater photon flux signals at 45 minutes indicate siRNA targeted a positive regulator of
NF-κB signaling. Conversely, at the 245 minute time point smaller values represent a
low signal during the resynthesis phase, which indicates a lack of full NF-κB
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transactivation and therefore siRNA knockdown of a positive regulator of NF-κB induced
transcription. Greater photon flux values correspond to over-activation of NF-κB
transcriptional activity, and therefore siRNA treatment targeted a negative transcriptional
regulator. Therefore, in Figure 4-6, an siRNA that acts on a positive regulator of both
the degradation and resynthesis phases will fall in the lower right quadrant, while a
negative regulator of both phases will be found in the upper left portion of the scatter
plot. The positive control well containing siRNA targeting TLR5, for example, should
prevent IκBα degradation at 45 minutes, which in turn, will inhibit reporter
transcriptional activation at 245 minutes. This is shown by the blue triangle
corresponding to TLR5 siRNA-treated wells falls in the lower right quadrant of the
scatter plot. IRAK1 and AKT, both known activators of the NF-κB signaling pathway,
were identified as hits in the screen, further verifying the validity of the results. The
screen also identified MAP2K2 and MAP2K3, among others, as kinases involved in
regulating the pathway.
In the screen, knockdown of NME3 caused reduced transcriptional activation by NF-κB
at 245 minutes, indicating NME3 was behaving as a positive regulator of NF-κB (Figure
4-6). Knockdown of NME3 by four individual siRNA sequences recapitulated the data in
the primary screen, although sequence 3 shows less inhibition of NF-κB signaling, likely
due to incomplete knockdown of NME3 (Figure 4-7). Conversely, over-expression of
plasmid-encoded NME3 in HCT116 cells induced higher levels of transcriptional
activation by NF-κB, demonstrating that NME3 behaves as a positive regulator of NF-κB
signaling in conditions of over-expression as well as under-expression (Figure 4-8).
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To better measure the contribution of NME3 in Salmonella-induced activation of NF-κB,
we constructed stable knockdowns of NME3 in HCT116 cells using shRNA lentiviral
constructs. Knockdown of NME3 by shRNA in wildtype HCT116 cells did indeed
interfere with NF-κB signaling pathways (Figure 4-9a). Compared to cells expressing a
scrambled shRNA sequence, cells expressing shRNA targeted to NME3 show slightly
less reporter degradation and much less resynthesis of the reporter during the
transcriptional activation phase. The responsiveness of a purely transcriptional reporter
fusion was also tested in these cell lines. As seen in NME3 knockdown cells expressing
the κB5IκBαFLuc reporter, cells expressing a κB5FLuc construct show considerably
less NF-κB-driven transcriptional activation following Salmonella stimulation (Figure 49b). Finally, semi-quantitative PCR confirms that NME3 mRNA in targeted shRNAexpressing cells is indeed reduced to much lower levels compared to cells containing a
non-targeting shRNA construct (Figure 4-9c).

4.5 Discussion
The NF-κB pathway specifically relies on kinases to effectively transmit signals from the
extracellular space into activation of transcription in the nucleus. Kinases, which
phosphorylate other proteins, often have an activating role in a signal transduction
pathway, and this holds true for the NF-κB signaling pathway as well. For instance, the
IκB kinase IKK, is rapidly phosphorylated in response to innate immune stimuli and
downstream signaling requires such IKK activation. The mechanism of IKK
phosphorylation is not fully understood, but multiple kinases have been proposed,
including RIP, TAK1, MAP3K14 and MAP3K1 as well as IKK itself through
autophosphorylation [8]. Perhaps each of these kinases has a distinct role in IKK
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activation. As there are multiple upstream stimuli capable of activating IKK, i.e., TNFα,
LPS, flagellin, multiple kinases likely exist to transmit these signals. NF-κB can also be
directly phosphorylated [9]. Cyclic AMP-dependent protein kinase (PKA)
phosphorylates the p65 subunit of NF-κB on a specific serine residue, which activates
transcriptional activity of NF-κB by enhancing DNA binding and aiding in transcriptional
co-activator recruitment [9].
Although not all kinases previously implicated in NF-κB signaling appeared to modulate
the NF-κB signaling pathway in this high-throughput screen, multiple kinases that have
been linked to the pathway did affect reporter activity in the screen. Notably, IRAK1, a
kinase with a central involvement to TLR signal transduction, is revealed in the screen as
a positive regulator at 45 minutes and this correlates with its known role in IKK
activation [10]. At 245 minutes, AKT is identified by the screen as a positive regulator
of NF-κB, and indeed, Akt has been shown to play a role in full NF-κB activation and to
promote nuclear NF-κB transactivation [11, 12]. Still, numerous kinases with wellaccepted important functions in the NF-κB pathway did not appear as hits in the highthroughput screen. In the cases of these kinases, such as IKKβ, there are several possible
reasons for lack of detection. First, the specific kinase may be expressed in such high
levels, that siRNA knockdown is insufficient to reduce the protein levels enough to affect
signaling. Alternatively, if loss of a specific kinase is toxic the host cell may have
compensating pathways to cope with loss of the kinase, thus preventing any phenotypic
change. Third, not all physiologically important kinases necessarily appear as high
stringency hits in published screens, revealing the complexity of systems and their
regulation.
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Interestingly, one hit uncovered by the high-throughput siRNA screen was the kinase
PTK6. PTK6 is a tyrosine kinase linked to over-expression in multiple tumor types[13,
14]. Recent research has demonstrated that plasma membrane-localized PTK6 enhances
cellular proliferation, survival and migration – all downstream effects of NF-κB
transcriptional activation[13]. Additionally, research has linked PTK6 to AKT activation
through ERBB3, all kinases identified in the screen as positive regulators of NF-κB
signaling. In this work, EGF signaling to AKT was enhanced by PTK6 overexpression
and mediated by ERBB3[15]. TLRs also have been shown to activate EGFR[16].
Perhaps, in this case, TLR may be activating EGFR, which in turn transmits the
proinflammatory signals downstream through PTK6, ERBB3 and AKT. This may
indicate a novel mechanism by which TLR5 may activate NF-κB signaling.
Although siRNA-mediated knockdown of both MAP2K2 and MAP2K3 gave
reproducible modulation of NF-κB, targeting known downstream MAP kinases via
chemical inhibitor showed no effect in my system (data not shown). This could be
explained by the identified kinases acting on other downstream proteins, as opposed to
their typical MAP kinase targets. Additionally, recent work identified MAP kinases as
important modulators of NF-κB-induced cytokine production in intestinal epithelial cells
with constitutively active NF-κB [17].

Because intestinal cancers often display high

levels of active NF-κB, MAPK activation in these cells may be required for full
inflammatory-mediated NF-κB transcriptional activation [18]. Perhaps this effect is the
underlying reason for the seemingly important contribution of MAP2K2 and MAP2K3 in
HCT116 colon carcinoma cells seen here.
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Targeted siRNA sequences to the nucleotide diphosphate kinase NME3 had a drastic
effect on NF-κB activation. NME3 is one of eight human nucleotide diphosphate kinase
genes [19]. These genes are capable of utilizing ATP to form non-ATP NTPs through
their catalytic kinase domain, but have also been attributed with a large variety of
potential functions from apoptosis regulation to cell migration to transcriptional
activation [20]. Two homologues of NME3, NME1 and NME2, have been studied in
much more detail than NME3 [20]. NME2 has demonstrated transcriptional activation of
cMyc, a noted oncogene [21]. NME3 shows about 65% homology with NME2, and has
an additional 17 amino acid N-terminal tail [20, 22]. NME3 has also been shown to
activate integrin expression and adhesion characteristics– a known downstream target of
NF-κB [23]. Perhaps, like NME2, NME3 acts as a transcription factor, and potentiates
the action of NF-κB. Follow-up analysis on NME3 would likely include investigating the
role of NME3 in co-activating NF-κB-dependent transcription downstream of other
stimuli, such as TNFα or IL-1β. Also, DNA-binding studies may help clarify whether
NME3 binds DNA to help co-activate transcription, similar to its homolog, NME2.
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4.6 Tables
Table 4-1 Kinases Modulating the NF-κB Pathway

Gene
name
ACVR1
ACVR1B
ADRBK2
AK5
AKAP3
AKAP9
AKT1
ALPK2
ALS2CR7
APEG1
ARK5
BLK
BMX
BTK
CALM3
CAMK2B
CAMK2G
CAMK4

Gene function
activin A receptor, type I
activin A receptor, type IB
adrenergic, beta, receptor kinase 2
adenylate kinase 5
A kinase (PRKA) anchor protein 3
A kinase (PRKA) anchor protein (yotiao) 9
v-akt murine thymoma viral oncogene homolog 1
alpha-kinase 2
amyotrophic lateral sclerosis 2 (juvenile)
chromosome region, candidate 7
aortic preferentially expressed protein 1
AMP-activated protein kinase family member 5
B lymphoid tyrosine kinase
BMX non-receptor tyrosine kinase
Bruton agammaglobulinemia tyrosine kinase
calmodulin 3 (phosphorylase kinase, delta)
calcium/calmodulin-dependent protein kinase
(CaM kinase) II beta
calcium/calmodulin-dependent protein kinase
(CaM kinase) II gamma
calcium/calmodulin-dependent protein kinase IV

NF-κB
regulatory
activity, 45
min α=0.1
NS
NS
NEGATIVE
NEGATIVE
NEGATIVE
NS
NS
POSITIVE
POSITIVE

NF-κB
regulatory
activity, 45
min α=0.02
NS
NS
NS
NS
NS
NS
NS
POSITIVE
NS

NF-κB
regulatory
activity, 245
min α=0.1
NEGATIVE
NEGATIVE
NS
NS
NS
NEGATIVE
POSITIVE
NS
NS

NF-κB
regulatory
activity, 245
min α=0.02
NS
NS
NS
NS
NS
NS
POSITIVE
NS
NS

NEGATIVE
NEGATIVE
POSITIVE
NS
NS
POSITIVE
NS

NS
NS
POSITIVE
NS
NS
NS
NS

NS
NS
NS
NEGATIVE
NEGATIVE
NS
NEGATIVE

NS
NS
NS
NEGATIVE
NEGATIVE
NS
NS

NEGATIVE

NS

NS

NS

POSITIVE

POSITIVE

NS

NS
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CCRK
CaMKIINalp
ha
CDK10
CDK3
CDK4
CDK5R2
CDK6
CDKN1B
CDKN2A
CKB
CKMT1
CNKSR1
CSK
CSNK1A1
CSNK1D
CSNK1G2
CSNK2A1
CSNK2A2
DGKA
DGKB
DGKE
DGKQ
DGUOK
DMPK
EGFR

cell cycle related kinase
calcium/calmodulin-dependent protein kinase II

POSITIVE
POSITIVE

NS
NS

POSITIVE
POSITIVE

POSITIVE
NS

cyclin-dependent kinase (CDC2-like) 10
cyclin-dependent kinase 3
cyclin-dependent kinase 4
cyclin-dependent kinase 5, regulatory subunit 2
(p39)
cyclin-dependent kinase 6
cyclin-dependent kinase inhibitor 1B (p27, Kip1)
cyclin-dependent kinase inhibitor 2A (melanoma,
p16, inhibits CDK4)
creatine kinase, brain
creatine kinase, mitochondrial 1 (ubiquitous)
connector enhancer of kinase suppressor of Ras 1
c-src tyrosine kinase
casein kinase 1, alpha 1
casein kinase 1, delta
casein kinase 1, gamma 2
casein kinase 2, alpha 1 polypeptide
casein kinase 2, alpha prime polypeptide
diacylglycerol kinase, alpha 80kDa
diacylglycerol kinase, beta 90kDa
diacylglycerol kinase, epsilon 64kDa
diacylglycerol kinase, theta 110kDa
deoxyguanosine kinase
dystrophia myotonica-protein kinase
epidermal growth factor receptor (erythroblastic

POSITIVE
NEGATIVE
NS
NEGATIVE

POSITIVE
NS
NS
NEGATIVE

NS
NS
NEGATIVE
NS

NS
NS
NS
NS

NS
NS
POSITIVE

NS
NS
NS

NEGATIVE
POSITIVE
NS

NEGATIVE
NS
NS

NS
NS
NEGATIVE
POSITIVE
POSITIVE
NS
NS
NS
POSITIVE
NS
POSITIVE
NS
NS
POSITIVE
NS
NEGATIVE

NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
POSITIVE
NS
NS

NEGATIVE
NEGATIVE
NS
NS
NS
NEGATIVE
NEGATIVE
NEGATIVE
NS
NEGATIVE
NS
NEGATIVE
POSITIVE
NS
NEGATIVE
NS

NS
NS
NS
NS
NS
NEGATIVE
NEGATIVE
NS
NS
NS
NS
NS
NS
NS
NEGATIVE
NS
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EPHA1
EPHA2
EPHA3
EPHA4
EPHA5
EPHA7
EPHA8
EPHB2
ERBB3
ERN2
FASTK
FER
FES
FGFR2

FGFR4
FLT3LG
GK
GK2
GNE

leukemia viral (v-erb-b) oncogene homolog,
avian)
EPH receptor A1
EPH receptor A2
EPH receptor A3
EPH receptor A4
EPH receptor A5
EPH receptor A7
EPH receptor A8
EPH receptor B2
v-erb-b2 erythroblastic leukemia viral oncogene
homolog 3 (avian)
endoplasmic reticulum to nucleus signalling 2
FAST kinase
fer (fps/fes related) tyrosine kinase
(phosphoprotein NCP94)
feline sarcoma oncogene
fibroblast growth factor receptor 2 (bacteriaexpressed kinase, keratinocyte growth factor
receptor, craniofacial dysostosis 1, Crouzon
syndrome, Pfeiffer syndrome, Jackson-Weiss
syndrome)
fibroblast growth factor receptor 4
fms-related tyrosine kinase 3 ligand
glycerol kinase
glycerol kinase 2
glucosamine (UDP-N-acetyl)-2-epimerase/Nacetylmannosamine kinase

NEGATIVE
NS
POSITIVE
POSITIVE
POSITIVE
NEGATIVE
NS
POSITIVE
POSITIVE

NS
NS
POSITIVE
NS
NS
NS
NS
POSITIVE
POSITIVE

POSITIVE
POSITIVE
NS
NS
NS
NS
POSITIVE
POSITIVE
NS

NS
NS
NS
NS
NS
NS
NS
POSITIVE
NS

NS
NS
POSITIVE

NS
NS
NS

NEGATIVE
POSITIVE
POSITIVE

NS
NS
NS

NS
POSITIVE

NS
POSITIVE

NEGATIVE
POSITIVE

NS
NS

NS
NEGATIVE
NS
NS
NEGATIVE

NS
NS
NS
NS
NS

NEGATIVE
NS
NEGATIVE
POSITIVE
NS

NS
NS
NS
NS
NS
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GRK5
GSK3A
GSK3B
HK1
HUNK
IHPK3
IKBKAP

IRAK1
IRAK2
ITK
ITPKA
KDR
KHK
LCK
LOC375449
LOC400301

LRRK2
LTK
LYN
MAP2K2

G protein-coupled receptor kinase 5
glycogen synthase kinase 3 alpha
glycogen synthase kinase 3 beta
hexokinase 1
hormonally upregulated Neu-associated kinase
inositol hexaphosphate kinase 3
inhibitor of kappa light polypeptide gene
enhancer in B-cells, kinase complex-associated
protein
interleukin-1 receptor-associated kinase 1
interleukin-1 receptor-associated kinase 2
IL2-inducible T-cell kinase
inositol 1,4,5-trisphosphate 3-kinase A
kinase insert domain receptor (a type III receptor
tyrosine kinase)
ketohexokinase (fructokinase)
lymphocyte-specific protein tyrosine kinase
similar to microtubule associated testis specific
serine/threonine protein kinase
similar to protein kinase CHK2 isoform b;
checkpoint-like protein CHK2; serine/threonineprotein kinase CHK2; CHK2 (checkpoint, S.pombe)
homolog
leucine-rich repeat kinase 2
leukocyte tyrosine kinase
v-yes-1 Yamaguchi sarcoma viral related
oncogene homolog
mitogen-activated protein kinase kinase 2

NEGATIVE
POSITIVE
NS
NS
POSITIVE
POSITIVE
NS

NS
POSITIVE
NS
NS
NS
POSITIVE
NS

NS
POSITIVE
NEGATIVE
NEGATIVE
NS
NS
POSITIVE

NS
POSITIVE
NS
NS
NS
NS
POSITIVE

POSITIVE
POSITIVE
NEGATIVE
POSITIVE
POSITIVE

POSITIVE
NS
NS
POSITIVE
POSITIVE

NS
NS
NS
NS
NS

NS
NS
NS
NS
NS

NS
POSITIVE
NS

NS
POSITIVE
NS

NEGATIVE
NS
NEGATIVE

NS
NS
NS

NEGATIVE

NS

NS

NS

POSITIVE
POSITIVE
POSITIVE

NS
NS
NS

NS
NS
NS

NS
NS
NS

POSITIVE

POSITIVE

POSITIVE

POSITIVE
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MAP2K3
MAP2K6
MAP2K7
MOS
MAP3K12
MAP3K3
MAPK10
MAPK14
MAPK6
MAPK7
MAPKAP1
MAPKBP1
MET
MGC40579
NEK1
NEK2
NEK3
NEK8
NME2
NME3
PACSIN2
PANK2

mitogen-activated protein kinase kinase 3
mitogen-activated protein kinase kinase 6
mitogen-activated protein kinase kinase 7
v-mos Moloney murine sarcoma viral oncogene
homolog
mitogen-activated protein kinase kinase kinase 12
mitogen-activated protein kinase kinase kinase 3
mitogen-activated protein kinase 10
mitogen-activated protein kinase 14
mitogen-activated protein kinase 6
mitogen-activated protein kinase 7
mitogen-activated protein kinase associated
protein 1
mouse mitogen-activated protein kinase binding
protein 1-like
met proto-oncogene (hepatocyte growth factor
receptor)
hypothetical protein MGC40579
NIMA (never in mitosis gene a)-related kinase 1
NIMA (never in mitosis gene a)-related kinase 2
NIMA (never in mitosis gene a)-related kinase 3
NIMA (never in mitosis gene a)- related kinase 8
non-metastatic cells 2, protein (NM23B)
expressed in
non-metastatic cells 3, protein expressed in
protein kinase C and casein kinase substrate in
neurons 2
pantothenate kinase 2 (Hallervorden-Spatz

POSITIVE
POSITIVE
NEGATIVE
POSITIVE

POSITIVE
NS
NS
NS

POSITIVE
NS
NS
NS

POSITIVE
NS
NS
NS

NS
POSITIVE
NS
POSITIVE
NS
NS
NS

NS
NS
NS
NS
NS
NS
NS

POSITIVE
NS
POSITIVE
NEGATIVE
POSITIVE
POSITIVE
POSITIVE

NS
NS
NS
NEGATIVE
POSITIVE
NS
NS

NS

NS

POSITIVE

NS

POSITIVE

NS

NS

NS

POSITIVE
POSITIVE
NS
NS
POSITIVE
POSITIVE

POSITIVE
NS
NS
NS
NS
NS

NS
NS
NEGATIVE
POSITIVE
NS
NS

NS
NS
NS
NS
NS
NS

NS
NEGATIVE

NS
NS

POSITIVE
NS

POSITIVE
NS

NS

NS

POSITIVE

NS
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PBK
PCTK3
PDGFRA
PDGFRB
PDK1
PDK2
PDK3
PDLIM5
PFKFB2
PHKA1
PHKG1
PIK3CD
PIK3CG
PIK3R2
PIK3R4
PIK4CB
PIM1
PIM2
PKN2

syndrome)
PDZ binding kinase
PCTAIRE protein kinase 3
platelet-derived growth factor receptor, alpha
polypeptide
platelet-derived growth factor receptor, beta
polypeptide
pyruvate dehydrogenase kinase, isoenzyme 1
pyruvate dehydrogenase kinase, isoenzyme 2
pyruvate dehydrogenase kinase, isoenzyme 3
PDZ and LIM domain 5
6-phosphofructo-2-kinase/fructose-2,6biphosphatase 2
phosphorylase kinase, alpha 1 (muscle)
phosphorylase kinase, gamma 1 (muscle)
phosphoinositide-3-kinase, catalytic, delta
polypeptide
phosphoinositide-3-kinase, catalytic, gamma
polypeptide
phosphoinositide-3-kinase, regulatory subunit 2
(p85 beta)
phosphoinositide-3-kinase, regulatory subunit 4,
p150
phosphatidylinositol 4-kinase, catalytic, beta
polypeptide
pim-1 oncogene
pim-2 oncogene
protein kinase N2

POSITIVE
NS
NS

POSITIVE
NS
NS

POSITIVE
POSITIVE
NS

POSITIVE
POSITIVE
NS

NS

NS

NEGATIVE

NS

NEGATIVE
POSITIVE
NEGATIVE
NEGATIVE
POSITIVE

NEGATIVE
POSITIVE
NS
NS
NS

NEGATIVE
NS
NEGATIVE
NS
NS

NS
NS
NS
NS
NS

NS
POSITIVE
POSITIVE

NS
NS
POSITIVE

NEGATIVE
NS
POSITIVE

NS
NS
POSITIVE

NS

NS

POSITIVE

POSITIVE

NEGATIVE

NS

NS

NS

NS

NS

NEGATIVE

NS

POSITIVE

POSITIVE

NS

NS

NEGATIVE
NS
POSITIVE

NEGATIVE
NS
POSITIVE

NS
NEGATIVE
NS

NS
NS
NS
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PKN3
PLK1
PRKAG1
PRKAR1B
PRKAR2A
PRKAR2B
PRKCABP
PRKCDBP
PRKD1
PRKG2
PRKX
PRKY
PSKH1
PTK6
RAF1
RPS6KA1
DCAMKL1
RPS6KB1
RPS6KB2
RPS6KL1

protein kinase N3
polo-like kinase 1 (Drosophila)
protein kinase, AMP-activated, gamma 1 noncatalytic subunit
protein kinase, cAMP-dependent, regulatory,
type I, beta
protein kinase, cAMP-dependent, regulatory,
type II, alpha
protein kinase, cAMP-dependent, regulatory,
type II, beta
protein kinase C, alpha binding protein
protein kinase C, delta binding protein
protein kinase D1
protein kinase, cGMP-dependent, type II
protein kinase, X-linked
protein kinase, Y-linked
protein serine kinase H1
PTK6 protein tyrosine kinase 6
v-raf-1 murine leukemia viral oncogene homolog
1
ribosomal protein S6 kinase, 90kDa, polypeptide
1
doublecortin and CaM kinase-like 1
ribosomal protein S6 kinase, 70kDa, polypeptide
1
ribosomal protein S6 kinase, 70kDa, polypeptide
2
ribosomal protein S6 kinase-like 1

NS
POSITIVE
NEGATIVE

NS
NS
NS

POSITIVE
POSITIVE
NS

NS
NS
NS

NEGATIVE

NS

NS

NS

NEGATIVE

NEGATIVE

POSITIVE

NS

NEGATIVE

NS

NS

NS

NEGATIVE
NS
POSITIVE
NS
NS
NS
NS
POSITIVE
NEGATIVE

NS
NS
NS
NS
NS
NS
NS
NS
NS

NS
POSITIVE
POSITIVE
POSITIVE
POSITIVE
POSITIVE
NEGATIVE
NS
NS

NS
NS
NS
NS
NS
NS
NS
NS
NS

POSITIVE

NS

NS

NS

NEGATIVE
NS

NEGATIVE
NS

NS
NEGATIVE

NS
NS

POSITIVE

NS

NS

NS

POSITIVE

NS

NS

NS
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RYK
SNF1LK
STK22D
STK25
STK32C
STK11
TAOK1
TEK
TESK1
TGFBR2
TIE1
TNK2
TYRO3
ULK2

RYK receptor-like tyrosine kinase
SNF1-like kinase
serine/threonine kinase 22D (spermiogenesis
associated)
serine/threonine kinase 25 (STE20 homolog,
yeast)
serine/threonine kinase 32C
serine/threonine kinase 11 (Peutz-Jeghers
syndrome)
TAO kinase 1
TEK tyrosine kinase, endothelial (venous
malformations, multiple cutaneous and mucosal)
testis-specific kinase 1
transforming growth factor, beta receptor II
(70/80kDa)
tyrosine kinase with immunoglobulin-like and
EGF-like domains 1
tyrosine kinase, non-receptor, 2
TYRO3 protein tyrosine kinase
unc-51-like kinase 2 (C. elegans)

NS
NS
POSITIVE

NS
NS
POSITIVE

POSITIVE
NEGATIVE
POSITIVE

NS
NS
NS

POSITIVE

NS

NS

NS

NS
POSITIVE

NS
NS

NEGATIVE
NS

NS
NS

NS
NEGATIVE

NS
NS

POSITIVE
NS

NS
NS

POSITIVE
NEGATIVE

POSITIVE
NEGATIVE

POSITIVE
POSITIVE

NS
POSITIVE

NEGATIVE

NS

NS

NS

NEGATIVE
NEGATIVE
NEGATIVE

NS
NEGATIVE
NS

NS
NS
NS

NS
NS
NS

128

4.7 Figures

Figure 4-1

Figure 4-1: Real-time activation of NF-κB signaling by Salmonella Typhimurium.
HCT116 cells transiently transfected with pκB5IκBαFLuc were stimulated with heatkilled Salmonella at T=0 and imaged for reporter activity every 5 minutes for 6 hours. (a)
Photon flux images obtained every 20 minutes are shown. (b) Data are displayed as the
fold-initial photon flux values. Imaging parameters: acquisition time, 60 sec; binning, 4;
filter, open; f stop, 1; FOV, 23 cm.
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Figure 4-2

Figure 4-2: LPS, Peptidoglycan and NOD ligands do not significantly contribute to
NF-κB activation in HCT116 cells in response to Salmonella. HCT116 cells stably
expressing κB5IκBαFLuc were stimulated with the indicated ligand at T=0 and imaged
for reporter activity every 5 minutes for 6 hours. Data is displayed as normalized photon
flux values (Fold-initial, fold-vehicle). Imaging parameters: acquisition time, 60 sec;
binning, 8; filter, open; f stop, 1; FOV, 20 cm(a,c) 15 cm(b).
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Figure 4-3

Figure 4-3: Salmonella flagellin activates NF-κB signaling in HCT116 colon
carcinoma cells. HCT116 cells stably expressing κB5IκBαFLuc were stimulated with
heat-killed wild-type Salmonella, fliC-, fjB-, or fliC-/fjB- at T=0 and imaged for reporter
activity every 5 minutes for 6 hours. Data is displayed as normalized photon flux values
(Fold-initial, fold-vehicle). Imaging parameters: acquisition time, 60 sec; binning, 8;
filter, open; f stop, 1; FOV, 20 cm.
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Figure 4-4

Figure 4-4: A schematic of the high-throughput screening technique. (a)HCT116
cells stably expressing κB5IκBαFLuc were plated into 96-well plates. After a 24-hour
incubation, cells were transfected with siRNA and incubated for 48 hours more. To
image, cells were transferred into d-luciferin-containing media, allowed to equilibrate for
45 minutes, stimulated with heat-killed Salmonella and imaged for reporter activity at 0,
45 and 245 minutes. (b) Each siRNA library plate contained targeting siRNA in columns
2-11 and control siRNA constructs in columns 1 and 12, as indicated. Control wells
included: mock-transfected cells (blue, A1), vehicle-treated wells (yellow; E1, F1, G1,
H1), three non-targeting control sequences (turquoise, Qiagen Allstar Negative control,
132

F12; Qiagen scrambled siRNA, G12; Qiagen GFP siRNA, H12), TLR5-targetting siRNA
sequences (red, IDT, C1, C12, D1, D12), and a firefly luciferase-targeting PGL3 siRNA
(purple, Dharmacon Research Inc, A12, B12).
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Figure 4-5

Figure 4-5: High-throughput screening data. Normalized photon flux data for 691
targeted kinases is shown at 45(a) and 245(b) minutes after Salmonella situation. Data is
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the average of three replicates. Dotted blue and dashed red lines show significance cutoffs for low (α = 0.1) and high (α = 0.02) stringency targeted error rates, respectively.
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Figure 4-6

a
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b

Figure 4-6: MAP2K2, MAP2K3 and NME3 act as positive regulators of Salmonellainduced NF-κB pathways. (a) A schematic diagram shows the proposed regulatory
activity on NF-κB by kinase targets in each of four quadrants in the plot. (b) The
normalized photon flux data from the primary screen at 45 minutes and 245 minutes are
plotted on the x- and y- axes, respectively. Highlighted points show data from specific
screening hits and TLR5 control wells.
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Figure 4-7

Figure 4-7: NME3 knockdown inhibits NF-κB. HCT116 cells stably expressing
κB5IκBαFLuc and transfected with the indicated siRNA constructs were stimulated
with heat-killed Salmonella and imaged for reporter activity every 5 minutes for 6 hours.
Data is displayed as normalized photon flux values (fold-initial, fold-untreated).
Individual siRNA sequences targeting NME3 show reduced IκBαFLuc reporter
responsiveness. Imaging parameters: acquisition time, 60 sec; binning, 8; filter, open; f
stop, 1; FOV, 12 cm.
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Figure 4-8

Figure 4-8: NME3 over-expression induces NF-κB transcriptional activation.
HCT116 cells were transfected with pκB5IκBαFLuc and the indicated plasmid
constructs and stimulated with heat-killed Salmonella and imaged for reporter activity
every 5 minutes for 6 hours. Data is displayed as normalized photon flux values (foldinitial, fold-untreated). Plasmid-based over-expression of NME3 induces overexpression of NF-κB transcriptional targets. Imaging parameters: acquisition time, 60
sec; binning, 8; filter, open; f stop, 1; FOV, 12 cm.
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Figure 4-9

140
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Figure 4-9: Targeting NME3 by shRNA reduces NF-κB responsiveness. (a) HCT116
cells were subjected to lentiviral knockdown with the indicated shRNA constructs and
transfected with the pκB5IκBαFLuc plasmid. Cells were then stimulated with heatkilled Salmonella and imaged for reporter activity every 5 minutes for 6 hours. Data is
displayed as normalized photon flux values (fold-initial, fold-untreated). Imaging
parameters: acquisition time, 30 sec; binning, 8; filter, open; f stop, 1; FOV, 15 cm. (b)
HCT116 cells were subjected to lentiviral knockdown with the indicated shRNA
constructs and transfected with the pκB5FLuc plasmid. Imaging was performed at 0,
2, 4, 6, and 7 hours following stimulation with Salmonella. Data is displayed as
normalized photon flux values (fold-initial, fold-untreated). IVIS 50 Imaging parameters:
acquisition time, 10 sec; binning, 8; filter, open; f stop, 1; FOV, 12 cm. (c) Semiquantitative PCR verifies knockdown of NME3 mRNA in shRNA-expressing HCT116
cells. GAPDH mRNA levels are shown as a control.
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CHAPTER FIVE
A High-Throughput siRNA Screen to Identify Novel
Host Phosphatases Involved in Regulation of Salmonella
Induction of Inflammation
5.1 Introduction
NF-κB is a key transcription factor and mediator of human innate immunity and stressresponse pathways. The protein can be activated by a number of different stimulatory
signals, including cytokines, microbial PAMPs and reactive oxygen species (ROS). One
major outcome of activated NF-κB signaling is the activation of genes involved in
promoting cellular survival and inhibiting apoptosis. Unregulated NF-κB signaling,
therefore, can lead to increased levels of cellular proliferation and has been linked to
cancer and other chronic inflammatory diseases [1].
Phosphatases are key players in many host signal transduction pathways and are known
to specifically modulate the NF-κB pathway at several instances. For example, the
phosphatase PP-2A acts to dephosphorylate IKKβ [2]. Also, WIP1 phosphatase acts to
directly dephosphorylate an activating serine phosphorylation on the p65 subunit of NFκB, thereby inhibition NF-κB activity [3].
Although other studies have identified novel phosphatase modulators of NF-κB signaling,
these studies most often utilize TNFα as the NF-κB-stimulating ligand. Yet, the NF-κB
pathway is activated by multiple other stimuli that lead to different downstream signaling
intermediates. For example, many of the proteins directly downstream of TLR activation
are not required for TNFα-induced signaling and different TLRs recruit different adapters
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to transduce their signals. Therefore, novel phosphatase actions may be discovered by
studying the NF-κB pathway downstream of TLR signaling as well.
To investigate the contribution of individual phosphatases to Salmonella-induced
activation of NF-κB, I performed an siRNA screen. By imaging the degradation and
resynthesis of an NF-κB-driven IκBα-FLuc reporter, I could study the individual
contributions of each phosphatase in two separate phases of NF-κB pathway activation.

5.2 Methods
Cell lines and culture conditions: HCT116 cells were a gift of Bert Vogelstein and
cultured according to ATCC directions. All stably transfected HCT116 cells were
cultured in 0.5 µg/ml puromycin.
Salmonella strains: Salmonella Typhimurium strain SL1344 was used for all
experiments.
Creation of a κB5IκBαFLuc-expressing HCT116 stable cell line: HCT116 cells at 95%
confluency were co-transfected with 10 µg of pκB5IκBαFLuc and 3 µg of pIRES-puro
plasmid DNA using Fugene 6 in 10 cm dishes. After 24 hours the media was replaced
with fresh cell media. Twenty-four hours later the cells were split at multiple dilutions
into media containing 0.5µg/ml puromycin to select for stable transformants. After two
weeks, isolated cell colonies were imaged to check for reporter gene expression and
bioluminescent colonies were harvested and expanded. The HCT116 stable cells were
continuously cultured in the presence of 0.5µg/ml puromycin to maintain expression of
the reporter plasmid.
High-throughput screen: siRNA screening was performed in white, clear-bottomed, 96well culture plates using a Beckman-Coulter Core robotics system, including an FX
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liquid handler, controlled by the Sagian graphical method development tool (SAMI
scheduling software). HCT116 cells stably expressing pκB5IκBαFLuc were seeded at
15,000 cells per well and allowed to attach for 24 hours. Forward transfection was
performed with a 96 multichannel head on the FX liquid handler, adding 0.5 µl/well of
media-complexed R1 Transpass (NEB) to the aliquotted siRNA library (Kinase siRNA
set v2; Qiagen Inc.) in a 96-well reaction plate and allowed to incubate for 15 minutes.
Experimental siRNA oligos were arrayed in columns 2-11 of each plate and individual
controls comprising vehicle-treated wells, a non-targeting control sequence (Qiagen
Allstar Negative control), TLR5-targetting siRNA sequences (IDT), and a firefly
luciferase-targeting PGL3 siRNA (Dharmacon Research Inc.) were placed manually in
columns 1 and 12. After incubation of siRNA complexes, 100 µl was added to each well
of a plate with cells (x3 plates) using the FX liquid handler, yielding a final concentration
of ~50 nM siRNA/well. Plates were maintained at 37ºC and 5% CO 2 for 48 hours. At
this time, media were aspirated and replaced with 180 µl imaging media (colorless
DMEM supplemented with 10% heat inactivated FBS and 150 µg/ml d-luciferin) and the
cells were allowed to equilibrate for 45 minutes. After equilibrating, 20 µl of stimulus
(1:100 dilutions of heat-killed Salmonella cultures) or control (LB broth) were added to
each well. Bioluminescent readings were obtained on an EnVision plate reader
(PerkinElmer) immediately following stimulus, at 45 minutes post-stimulation and at 245
minutes post-stimulation. After the final luminescent reading, 20 µl of rezasurin dye was
added to all wells, allowed to incubate for 2 hours at 37ºC and monitored on a FLUOstar
OPTIMA fluorescence reader (BMG Labtech; excitation, 544 nm, emission, 590 nm).

147

Data analysis: Initially, the signal in each well was normalized to a plate-matched
control well containing a non-targeting siRNA sequence to facilitate experiment-wide
analysis. Then, the differences in the log 2 values of the normalized data between 0
minutes and 45 or 245 minutes were averaged across triplicate siRNA experimental
replicates. Screening hits were selected by quartile analysis of the normalized kinase
library data. To perform the quartile analysis, median (Q2), first (Q1) and third (Q3)
quartile values were calculated. From these values, the upper and lower boundaries for
hit selection were calculated as Q3 + 2c(Q3 –Q2) and Q1 – 2c(Q2-Q1), respectively, for
c = 0.9529 corresponding to a targeted error rate (α = 0.05).

5.3 Results
To identify novel host factors involved in Salmonella-induced activation of innate
immunity, an siRNA screen targeting all known and predicted host phosphatases was
performed in HCT116 colon carcinoma cells. The HCT116 colon carcinoma cells were
stably transfected with a plasmid containing five tandem NF-κB binding sites driving an
IκBα-FLuc fusion reporter construct. This reporter permitted imaging two separate
stages in the activation of the NF-κB pathway. The first stage is the early degradation of
the fusion reporter, representing degradation of IκBα, the negative regulator NF-κB,
which preceeds nuclear translocation NF-κB. Then, the second stage represents the
transcriptional activation mediated by NF-κB, which drives reporter synthesis, due to the
five tandem NF-κB binding sites. These two stages can be measured by an initial
decrease in bioluminescence, followed by a large increase in bioluminescent signal,
respectively. HCT116 cells stably expressing this reporter were treated with siRNA
constructs (2 sequences per well) targeting individual host phosphatases for 48 hours.
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Then, heat-killed preparations for Salmonella were added to stimulate NF-κB signaling.
The normalized data obtained from imaging at 45 minutes and 245 minutes are shown in
Figures 5-1a and b. Additionally, to combine the information acquired for each targeted
phosphatase, the data can be plotted with the 45-minute signals on the x-axis and the 245
minute signals on the y-axis (Figure 5-2). In this plot, positive values along the x-axis
correspond to phosphatase knockdowns that induced less reporter degradation than
control, indicating phosphatases that positively modulate the degradation phase of NF-κB
signaling. Conversely negative x-values represent wells that induced more reporter
degradation and therefore represent phosphatses with a negative regulatory role in NF-κB
signaling. At 245 minutes, represented by y-values, positive and negative values
represent negative and positive regulators of NF-κB signaling, respectively. In this case,
data representing a phosphatase acting as a positive regulator of NF-κB signaling at both
time points will fall in the lower right quadrant of the plot, as in the case of the TLR-5
control siRNA. A summary of all statistically significant hits and their predicted
regulatory activity on NF-κB signaling are listed in Table 5-1.

5.4 Discussion
Salmonella is known to activate NF-κB signaling through activation of Toll-like
receptors in host cells. In order to identify potential novel phosphatases involved in
Salmonella-induced activation of host NF-κB signaling through bacterial flagellin, we
utilized a high-throughput siRNA screen. Interestingly, phosphatases are often credited
as negative regulatory proteins in signal transduction pathways, and the global highthroughput screening data obtained here seem to confirm this role. At both the 45 and
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245 minute time points, the majority of assayed phosphatases are negatively regulating
NF-κB signaling.
Several of the phosphatases identified as hits in the high throughput screen belong to the
PP2C family of phosphatases. PPM1A, PPM1G, and PPM1L are all phosphatases in the
PP2C family, a group of serine/threonine phosphatases found in eukaryotes that have
been shown to have roles in negative regulation of stress responses [4, 5]. WIP1
phosphatase also belongs to the PP2C family and has previously been shown to modulate
NF-κB signaling, but was not a hit in this high-throughput screen [3]. However the
experiments with WIP1 demonstrated its role in TNFα and IL-1β-induced signaling, and
perhaps WIP1 is less relevant to TLR-induced NF-κB signaling as studied here [3].
PPM1A has been shown to negatively regulate NF-κB signaling, and in previous work,
knockdown of PPM1A induced enhanced NF-κB nuclear translocation and downstream
gene activation, similar to the results in this high-throughput screen [4]. PPM1L and
PPM1G have demonstrated opposing roles in regulation of cellular stress response
pathways in previous work, verifying the data from this screen [5]. However, these
studies have demonstrated negative regulation of TNFα-induced activation of MAP
kinase and pro-apoptotic signaling by PPM1L and positive regulation by PPM1G, the
opposite of the effects observed in this screen [5]. Because NF-κB activation by TNFα
serves to prevent apoptosis, it could be reasoned that while PPM1L negatively regulates
TNFα induction of apoptosis, it effectively positively regulates TNFα induction of NF-κB
signaling, thereby creating roles for PPM1L and PPM1G in positive and negative
regulation of NF-κB signaling, respectively, as demonstrated here [6].
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Another phosphatase identified in the screen, PTPNS1, has also been shown to play an
important role in AKT activation following treatment with TNFα or IL-1β [7]. Because
AKT is likely involved in activation of NF-κB signaling, PTPNS1 may be required for
full activation of NF-κB downstream of TLR signaling as well [8]. Finally, in a study of
host lipid compounds called resolvins that regulate host inflammatory pathways, ALP1
was linked to cellular resolution of inflammation [9]. In this work, resolvin treatment
induce ALP1 expression, which reduced NF-κB activation and promoted resolution of
inflammation[9]. However, the researchers in the study claim the anti-inflammatory role
of ALP1 lies in its dephosphorylation of LPS, which detoxifies the bacterial product.
However, based on the data from the high-throughput screen performed here, the role of
ALP1seems more likely to be dephosphorylation of a common intermediate in TLR4 and
TLR5 signal transduction. It would be interesting to determine where ALP1 negatively
regulates NF-κB activation downstream of cytokine receptors, such as TNFR, as well.
The phosphatases identified here warrant further functional studies to better understand
their roles in modulation of NF-κB. ALP1 is of particular interest based on its
hypothesized role as a mediator of resolution of inflammation. Through further research
on ALP1 we may discover new ways to target over-active inflammatory responses.
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5.5 Tables
Table 5-1 Phosphatases Modulating the NF-κB Pathway

Gene name
ALPI
CTDSP2
DOLPP1
DUSP12
DUSP7
ENPP1
FBP1
G6PC
G6PC3
INPP5B
LHPP

LOC387870

Gene function
alkaline phosphatase, intestinal
CTD (carboxy-terminal domain, RNA polymerase II,
polypeptide A) small phosphatase 2
dolichyl pyrophosphate phosphatase 1
dual specificity phosphatase 12
dual specificity phosphatase 7
ectonucleotide pyrophosphatase/phosphodiesterase
1
fructose-1,6-bisphosphatase 1
glucose-6-phosphatase, catalytic (glycogen storage
disease type I, von Gierke disease)
glucose 6 phosphatase, catalytic, 3
inositol polyphosphate-5-phosphatase, 75kDa
phospholysine phosphohistidine inorganic
pyrophosphate phosphatase
similar to protein tyrosine phosphatase, receptor
type, Q isoform 1 precursor; glomerular mesangial
cell receptor protein-tyrosine phosphatase;
glomerular mesangial cell receptor protein-tyrosine
phosphatase precursor
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NF-κB
regulatory
activity, 45
min α=0.1
NEGATIVE

NF-κB
regulatory
activity, 45
min α=0.02
NS

NF-κB
NF-κB
regulatory
regulatory
activity, 245 activity, 245
min α=0.1
min α=0.02
NS
NS

NS
POSITIVE
NS
NS

NS
POSITIVE
NS
NS

POSITIVE
NS
NEGATIVE
POSITIVE

NS
NS
NS
NS

NS
NS

NS
NS

NEGATIVE
NEGATIVE

NS
NEGATIVE

NS
POSITIVE
NS

NS
POSITIVE
NS

NEGATIVE
POSITIVE
POSITIVE

NS
NS
NS

POSITIVE

POSITIVE

NS

NS

NS

NS

POSITIVE

POSITIVE

PHPT1
PLIP
PNKP

PPFIA4
PPM1A
PPM1G
PPM1L
PPP1CB
PPP1CC
PPP1R12C
PPP1R15B
PPP1R2
PPP1R3B
PPP1R3D
PPP1R3F
PPP1R8

phosphohistidine phosphatase 1
PTEN-like phosphatase
polynucleotide kinase 3'-phosphatase
protein tyrosine phosphatase, receptor type, f
polypeptide (PTPRF), interacting protein (liprin),
alpha 4
protein phosphatase 1A (formerly 2C), magnesiumdependent, alpha isoform
protein phosphatase 1G (formerly 2C), magnesiumdependent, gamma isoform
protein phosphatase 1 (formerly 2C)-like
protein phosphatase 1, catalytic subunit, beta
isoform
protein phosphatase 1, catalytic subunit, gamma
isoform
protein phosphatase 1, regulatory (inhibitor) subunit
12C
protein phosphatase 1, regulatory (inhibitor) subunit
15B
protein phosphatase 1, regulatory (inhibitor) subunit
2
protein phosphatase 1, regulatory (inhibitor) subunit
3B
protein phosphatase 1, regulatory subunit 3D
protein phosphatase 1, regulatory (inhibitor) subunit
3F
protein phosphatase 1, regulatory (inhibitor) subunit
8
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POSITIVE
NS
POSITIVE

POSITIVE
NS
NS

POSITIVE
POSITIVE
POSITIVE

NS
NS
NS

POSITIVE

NS

NS

NS

NS

NS

NEGATIVE

NS

NS
POSITIVE

NS
NS

NEGATIVE
POSITIVE

NEGATIVE
NS

NS

NS

NEGATIVE

NEGATIVE

NS

NS

NEGATIVE

NEGATIVE

POSITIVE

POSITIVE

NS

NS

POSITIVE

POSITIVE

NS

NS

NEGATIVE

NS

NS

NS

POSITIVE
NS

NS
NS

NS
NEGATIVE

NS
NS

NS

NS

NS

NS

NEGATIVE

NS

NEGATIVE

NS

PPP2R2C
PTPDC1
PTPN22
PTPNS1
PTPRB
PTPRR
PTPRV
RNGTT
SKIP

protein phosphatase 2 (formerly 2A), regulatory
subunit B (PR 52), gamma isoform
protein tyrosine phosphatase domain containing 1
protein tyrosine phosphatase, non-receptor type 22
(lymphoid)
protein tyrosine phosphatase, non-receptor type
substrate 1
protein tyrosine phosphatase, receptor type, B
protein tyrosine phosphatase, receptor type, R
protein tyrosine phosphatase, receptor type, V
RNA guanylyltransferase and 5'-phosphatase
skeletal muscle and kidney enriched inositol
phosphatase
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NS
POSITIVE

NS
POSITIVE

NEGATIVE
POSITIVE

NEGATIVE
POSITIVE

POSITIVE

POSITIVE

NS

NS

POSITIVE
NS
NEGATIVE
POSITIVE
NEGATIVE

POSITIVE
NS
NS
NS
NS

POSITIVE
NEGATIVE
NS
NS
NS

POSITIVE
NS
NS
NS
NS

NS

NS

NEGATIVE

NS

5.6 Figures

Figure 5-1
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Figure 5-1: High-throughput screening data. Normalized photon flux data for 206
targeted phosphatases is shown at 45(a) and 245(b) minutes after Salmonella stimulation.
Data is the average of three replicates. Dotted blue and dashed red lines show
significance cut-offs for low (α = 0.1) and high (α = 0.02) stringency targeted error rates,
respectively.
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Figure 5-2: PTPNS1, PPM1L, ALP1, PPM1A and PPM1G modulate Salmonellainduced NF-κB pathways. The normalized photon flux data from the primary screen at
45 minutes and at 245 minutes are plotted on the x- and y- axes, respectively.
Highlighted points show data from specific screening hits and TLR5 control wells.
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CHAPTER 6
Conclusions and Future Directions
6.1 Salmonella Interactions with Neoplastic Cells
In this work, Salmonella demonstrated invasion of cancer cells in vitro. However,
whether Salmonella are capable of invading host cells in a tumor in vivo remains to be
proven definitively. Existing data does seem to indicate, that in a tumor
microenvironment, the majority individual bacteria remain in the extracellular space [1].
This may prove to be an advantage, though, when using bacteria to deliver toxins to
tumors in vivo. The promoters identified in this work are regulated by a low pH
environment. While the intracellular pH in tumors is similar to that of normal cells, the
extracellular pH in the tumor microenvironment is particularly acidic [2]. Therefore, a
pH-regulated promoter would be specifically activated by extracellular bacteria in the
tumor microenvironment, but not by bacteria that had invaded tumor cells. This does
pose a problem since the toxin utilized to target the tumor must work on the surface of
the tumor cells or be internalized readily by tumor cells in the area. In this interest, Shiga
toxin is an ideal choice for cargo of a therapeutic bacterial vector. It can be produced
readily by bacteria and binds the glycosphingolipid globotriaosylceramide (Gb3) cellular
surface receptor. Gb3 levels are relatively low in normal tissues, but noted to be highly
expressed in multiple cancers [3]. By exploiting tumor -targeting bacteria expressing a
tumor-specific toxin under the control of a tumor microenvironment-induced promoter, a
highly specific bacterial-based therapeutic could be developed.
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Studies have also shown that Salmonella may be forming a biofilm in the tumor
microenvironment [4]. In recent work, microscopic analysis demonstrates bacterial
biofilm formation at the site of a tumor in vivo [4]. In addition, deletion of genes known
to be involved in Salmonella biofilm formation enhanced bacterial uptake into tumor
cells and immune cells [4]. The authors posited that perhaps bacteria are forming
biofilms in the tumor microenvironment to resist phagocytosis [4]. This work may
indicate bacterial biofilm genes are an additional set of tumor microenvironment-induced
promoters that could also be exploited in bacterial tumor-targeting studies.
Finally, it would be worthwhile to further characterize the regulation of the Salmonella
genes uncovered in this screen. For instance, other stimuli bacteria encounter during
transit through the acidic environments of the stomach and intestines may also induce
activation of the identified promoters. Other conditions bacteria may respond to during a
typical infection include oxygen concentration, osmolarity and acetate concentration , all
conditions that may also be relevant to growth in the tumor microenvironment [5].

6.2 How Neoplastic Cells Respond to Salmonella
Bacterial adaptation to the tumor microenvironment addresses only half of the
Salmonella-host interaction. Also at play are the host cells comprising a tumor likely
respond to the presence of a foreign organism by activating proinflammatory signaling.
In this work, I demonstrate the response of HCT116 colon carcinoma cells to Salmonella.
HCT116 cells respond predominantly to bacterial flagellin with a robust activation of NFκB signaling. Interestingly, the dynamics and amplitude of Salmonella-induced NF-κB
signaling differ from that of TNFα-induced signaling. Salmonella stimulation of
HCT116 cells induced less degradation of IκBα, but more and sustained NF-κB
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transcriptional activation compared to TNFα stimulation. Perhaps Salmonella and TNFα
are activating different downstream transcriptional programs of NF-κB. Microarray
analysis of Salmonella-treated versus TNFα-treated cells would provide a way to
interrogate the differences in downstream gene activation.
To identify novel kinases and phosphatases involved in detection of Salmonella and
activation of proinflammatory signaling, an siRNA high-throughput screen was utilized.
One striking observation from the screening data is that most kinases and phosphatases
have some effect on NF-κB signaling. This observation serves to highlight the vast
amount of interconnectivity between intracellular signaling pathways and must be
considered when analyzing screen data and selecting candidates for follow-up. Another
potential caveat of this high-throughput screen was the use of siRNA for target
knockdown, a known ligand of TLR3 [6]. While normalizing to negative control, nontargeting siRNA should account for this effect, TLR3 is also known to activate NF-κB
signaling, and therefore its potential effect should be acknowledged when choosing
candidate hits for further study. Additionally, TLR5-positive, TLR3-negative cell lines
may serve as a useful tool for follow-up studies.
In the high-throughput screen, two of the most significant hits at both phases of the
pathway tested (degradation and resynthesis) were MAP kinase kinases. Intriguingly,
IKK has a similar role to MAP kinase kinases in its signal transduction pathway in that its
activity is one kinase removed from proteins thought to act at the intracellular domain of
the activated cell surface receptor. It is tempting, therefore, to consider a model where all
pathways downstream of an activated TLR are interconnected and interdependent.
Perhaps proper progression of all signaling pathways downstream of a receptor is
161

required for appropriate signal transduction in any singular pathway. For instance,
blocking the activation of MAP2K2 or MAP2K3 may reprogram all downstream and
parallel intracellular signaling pathways, thus preventing IKK activation as well. This
indicates future studies of intracellular signaling should embrace a global view of cellular
pathways to fully understand the role of specific proteins.
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